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ABSTRACT
Purpose: Knowledge-based planning (KBP) leverages plan data from a database of previously
treated patients to inform the plan design of a new patient. This work investigated bladder and
rectum dose-volume prediction improvements in a common KBP method using a Pareto plan
database in VMAT planning for prostate cancer.
Methods: We formed an anonymized retrospective patient database of 124 VMAT plans for prostate
cancer treated at our institution. From these patient data, two plan databases were compiled. The
clinical plan database (CPD) contained planning data from each patient’s clinical plan, which were
manually optimized by various planners. The multi-criteria optimization database (MCOD)
contained Pareto plan data from plans created using a standardized MCO protocol. Overlap volume
histograms, incorporating fractional OAR volumes only within the treatment fields, were computed
for each patient and used to match new patient anatomy to similar database patients. For each
database patient, CPD and MCOD KBP predictions were generated for D10, D30, D50, D65, and D80
of the bladder and rectum in a leave-one-out manner. Prediction achievability was verified through a
re-planning study on a subset of 31 randomly selected database patients using the lowest KBP
predictions, regardless of plan database origin, as planning goals.
Results: MCOD model predictions were significantly lower (p < 0.001) than CPD model predictions
for all five bladder dose-volumes and rectum D50 (p = 0.004) and D65 (p < 0.001), while CPD model
predictions for rectum D10 (p = 0.005) and D30 (p < 0.001) were significantly less than MCOD model
predictions. KBP model predictions were statistically equivalent to re-planned values for all
predicted dose-volumes, excluding D10 of bladder (p = 0.03) and rectum (p = 0.04). Compared to
clinical plans, re-plans showed significant average reductions in Dmean for bladder (7.8 Gy; p < 0.001)
and rectum (9.4 Gy; p < 0.001), while maintaining statistically similar PTV, femoral head, and penile
bulb dose.

xiii

Conclusion: KBP dose-volume predictions derived from Pareto plans were lower overall than those
resulting from manually optimized clinical plans. A re-planning study showed the KBP dose-volume
predictions were achievable and led to significant reductions in bladder and rectum dose.
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CHAPTER 1. INTRODUCTION
1.1

BACKGROUND

1.1.1

RADIATION THERAPY TREATMENT DELIVERY AND PLANNING
Radiation therapy (or radiotherapy) is the use of high-energy radiation, such as x-rays,

gamma rays, electrons, or protons, to kill or damage cancer cells. Over half of all cancer patients will
receive some form of radiotherapy during the course of their treatment.1 Currently, there are two
main approaches to delivering the prescribed radiation dose: external beam radiotherapy (EBRT),
which involves large source-to-surface distances, or SSDs; and brachytherapy, which utilizes
radioisotopes to treat internally or with small SSDs. In EBRT, linear accelerators are used to
generate and direct megavoltage electrons or photons toward the cancer located within the patient.
Most modern linear accelerators support different options for delivering the prescribed
radiation dose to the target for a given patient and disease. 3D conformal radiotherapy (3DCRT)
collimates radiation fields of uniform intensity around lesions to simultaneously dose the target and
spare surrounding healthy tissues using multi-leaf collimators (MLCs), which are motorized sets of
thin, tungsten slabs that move in and out of the field to form different shapes.2 3DCRT was the first
delivery technique based on 3D anatomical information provided by computed tomography (CT)
scans. Access to 3D information allows more accurate delineations of targets and healthy organs and
conformal dose distributions compared to previous delivery methods based on 2D radiographic
projections.
Alternatively, fixed-field intensity modulated radiotherapy (IMRT) is a delivery technique
typically combining five to seven fixed radiation fields of spatially varying fluence patterns. Each
beam’s modulated intensity profiles are achieved by combining complex sequences of MLC leaf
travel, which are set to optimize the composite dose distribution. IMRT combines the non-uniform
fluence maps from each beam (aimed from different directions) to create highly conformal dose

1

distributions that improve target coverage and in sparing of normal tissues compared to 3DCRT.3,4
However, longer treatment delivery times and increased monitor units (MUs) are limitations for
IMRT treatments. The latter can increase radiation exposure to parts of the body distant from the
treatment field, whereas the former can impair patient comfort and reproducibility.5 In order to
overcome these deficiencies, arc-based or rotational treatment techniques were developed, where
radiation is delivered while rotating the linear accelerator about the target.
Volumetric modulated arc therapy (VMAT), one such rotational IMRT technique, delivers
intensity modulated fields by continuously varying three main parameters: rotation speed of the
linear accelerator gantry, MLC positions, and dose rate (Figure 1).6 VMAT dose is computed by
approximating a continuous arc with a large number of discrete segments. The non-uniform fluence
profiles and ensuing MLC sequences are optimized at each control point (each segment lies between
two control points) to create highly conformal intensity modulated dose distributions. Compared to
fixed-field IMRT, VMAT requires fewer MUs and provides a significantly shorter treatment time.7
Due to the relatively recent clinical implementation of VMAT, its overall dosimetric advantages over
fixed-field IMRT are uncertain. Some studies have reported potential benefits of VMAT for specific
treatment sites like the prostate, while others have found inconsistent dosimetric results between
IMRT and VMAT for head-and-neck treatments.7-12 Primarily owing to efficiency, VMAT has
quickly become a ubiquitous treatment technique for cases requiring intensity modulation.
Radiotherapy treatment planning is the process of defining how the prescribed dose is to be
delivered during treatment. More specifically, a treatment plan specifies the machine parameters to
produce the desired dose distribution for the given patient. These parameters can include the
number of beams, beam energy, beam shape, beam weight, gantry angle, intensity modulators (e.g.
wedges, tissue compensators, MLCs), and couch angle. Computerized treatment planning systems
(TPSs) are used to help determine these parameters to arrive at a customized treatment plan for each
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patient. Even with the assistance of computers, treatment plan design is time-consuming and highly
complex given the large number of parameters the must be specified.
Varying MLC Positions

Varying
Dose
Rate
Varying
Gantry
Speed

Figure 1: Diagram of a modern linear accelerator, highlighting the three varying parameters that
differentiate VMAT from other EBRT delivery techniques.13,14
There are two main approaches to treatment planning used today, each of which facilitate
specific delivery techniques. “Forward planning” is employed to design treatment plans for
conventional, uniform intensity techniques (e.g. 3DCRT). Forward planning is the process of
manually adjusting treatment parameters to obtain the desired dose distribution. If a patient is to be
treated with 3DCRT, for instance, the planners must manually find the appropriate machine and
treatment parameters to obtain an acceptable plan. This forward planning approach forces planners
to determine these parameters effectively by trial-and-error, where the dose must be computed and
evaluated each time a set of parameters is selected. Moreover, if the resulting dose distribution is not
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acceptable, the parameters are manually adjusted and the dose is recomputed for evaluation. These
iterations continue until the desired dose distribution is achieved.
Alternatively, “inverse planning” is used for planning more complex treatment delivery
techniques such as IMRT and VMAT. These techniques require many intricate MLC sequences for
each field or arc segment to generate the necessary modulated fluence patterns. Manually optimizing
these varying fluence maps and corresponding MLC sequences for each beam via forward planning
would prove prohibitively difficult and laborious.15 Therefore, inverse planning optimization
algorithms were developed and implemented into TPSs to plan these intensity modulated delivery
techniques. Inverse planning requires the planner to specify the clinical treatment criteria, after
which an optimization algorithm automatically determines modulated fluence maps for each beam
or arc segment that achieve the treatment goals. More specifically, the user defines clinical dosevolume constraints (i.e. the dose a fractional volume of a planning structure receives) for the target
and normal tissues, which are represented as cost objective functions for the optimization algorithm
to minimize. Once the optimizer generates a set of modulated fluence segments and beam
parameters for the given treatment objectives, the dose is computed and the dose distribution is
evaluated. If improvement is needed or the planner wants to assess a clinical trade-off, the planner
must adjust the initial dose-volume objectives and run another optimization. Additionally, clinical
inverse planning algorithms utilize a gradient-based search for optimal intensity profiles, which
usually requires multiple optimization rounds to ensure the solution reaches a global, and not a local,
minimum. This trial-and-error nature of inverse planning resembles that of forward planning, but
the two protocols differ in the parameters that planners modify after each iteration. Regardless,
inverse planning can become increasingly time-consuming for complicated cases, like head-and-neck
patients, that require the assessment of a large number of clinical trade-offs. Paired with the time
limitations of a clinical environment, this can limit the quality of inverse plans.
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While it drives the planning of IMRT techniques, inverse optimization reduces a threedimensional dose distribution into a set of dose objectives based on one-dimensional dose volume
histograms (DVHs). This dimensionality reduction in describing dose distributions underscores the
importance of selecting and adjusting optimal inverse planning objectives. Planners do not currently
know a priori what the fully optimal treatment plan is for a given patient, let alone the set of planning
objectives needed to arrive at that plan. Further, clinical dose-volume goals for normal tissues are
usually derived from population-based clinical studies (e.g. Emami et al.16, Quantitative Analysis of
Normal Tissue Effects in the Clinic17, Radiation Therapy Oncology Group studies, etc.), which have
recommended dose tolerances for clinical acceptability but do not provide any patient-specific
information. This, in addition to unique patient anatomies and the heuristic nature of inverse
planning, cause the quality of inversely optimized plans to be susceptible to planner bias and
subjectivity. These limitations of inverse planning have led studies to observe a plan quality
dependence on planner experience and “skill.”18 Batumalai et al. found within one institution that
more experienced planners were able to produce superior IMRT plans for a head-and-neck case
compared with less experienced planners, whose plans were also generally more difficult to deliver
accurately.19 Planner bias results in plan quality variations between planners and institutions, which
lead to sub-optimal plans that are clinically-acceptable but more sparing of organs at risk (OARs) is
possible.20,21 Nelms et al. observed a wide inter-planner variation in plan quality of one prostate
patient, which they quantified using a “Plan Quality Metric” (PQM) scoring mechanism. The PQM
algorithm combines 14 target and OAR dose metrics, each assigned a unique value function, to serve
as treatment goals from a hypothetical physician. With minimum and maximum possible PQM
values of -10 and 150 respectively, they saw a large range of 58.2-142.5 in PQM (mean of 116.9;
standard deviation of 16.4) over their 125 plan sample size. This variance in plan quality was
independent of TPS, delivery modality (IMRT versus rotational), beam angles, total MUs, and
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planner experience.22 Moore et al. performed a secondary study on the quality of plan data accrued
for the Radiation Therapy Oncology Group (RTOG) 0126 protocol comparing high dose to
standard dose 3DCRT/IMRT in patients with localized prostate cancer. They observed 42.9% of
219 patients with ≥5% excess risk, 9.1% with ≥10% excess risk, and 0.9% with ≥15% excess risk of
grade ≥2 rectal toxicities. This revealed how sub-optimal inverse planning can leave prostate patients
vulnerable to excess risk of rectal complications.23
Inverse planning has been shown to efficiently produce clinically-acceptable plans for
sophisticated delivery modalities such as VMAT. However, achieving a fully optimal plan via inverse
optimization requires substantial time and effort to iteratively explore the relevant clinical trade-offs.
Planners must often sacrifice plan quality for efficiency due to clinical time constraints. The trialand-error and heuristic nature of inverse planning can also introduce planner subjectivity and bias,
further affecting plan quality. Given these inverse planning deficiencies, novel planning methods and
optimization algorithms aiming to improve patient-specific plan quality and consistency have
become a focus in medical physics research.
1.1.2

MULTI-CRITERIA OPTIMIZATION
One such advanced optimization algorithm aiming to minimize the iterative and subjective

nature of inverse planning is called multi-criteria optimization (MCO). MCO planning allows for the
real-time assessment of clinical trade-offs by generating a database of Pareto optimal plans, which
are plans that are computationally feasible with respect to all constraints and no objective can be
improved without compromising another. While theoretically there are an infinite number of
fluence-based Pareto plans, the clinical implementation of MCO used in this study approximates this
Pareto solution surface through a discrete set of plans that emphasize user-specified planning
objectives (Figure 2). The first N discrete Pareto plans, where N is the number of specified trade-off
objectives, are called anchor plans and separately optimize each objective. The N+1th plan, called
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the “balance plan,” is a Pareto plan that optimizes each trade-off objective with equal weighting.
Additional auxiliary plans can be generated to better approximate the Pareto surface representation
if desired.

Figure 2: An example from RaySearch Laboratories of a three-dimensional Pareto surface for a
prostate plan with three MCO trade-off objectives. The planner can search over this surface in realtime to consider different clinical trade-offs.24
After a patient-specific database of fluence-based Pareto plans is constructed, the planner
can dynamically navigate over the computed solution space by adjusting weights assigned to each
trade-off objective. Then the selected fluence-based Pareto plan is segmented into a deliverable plan
through direct machine parameter optimization, which minimizes DVH differences between the
navigated plan and the deliverable plan to optimize MLC segments.25 Then finally, the clinical dose is
computed.
Early investigations into the clinical viability of MCO suggest it improves IMRT plan quality
and efficiency. Craft et al. reported an average IMRT planning time of five glioblastoma and five
pancreatic cancer patients of 12 minutes using MCO, compared to 135 minutes using traditional
inverse planning methods. The same study also found physicians blindly identified MCO IMRT
plans as superior compared to the clinical plan designed through standard inverse optimization.26
7

Kierkels et al. showed novice planners using MCO could create high-quality IMRT head-and-neck
plans with increased target dose homogeneity and reduced parotid dose compared with conventional
clinical plans created by experienced planners.27 Similar improvements in planning efficiency and
quality have been found for MCO VMAT planning.28,29 An example of the potential differences in
dose distributions between inverse planning and MCO planning is shown in Figure 3.

(a)

(b)

Figure 3: Example of dose distribution differences between inverse and MCO planning. The same
axial CT slice of the same prostate patient is shown with the inversely optimized clinical VMAT plan
on top (a) and a deliverable balance MCO VMAT plan on bottom (b). A noticeable reduction in
OAR dose is shown in the MCO plan, particularly for both femoral heads.
While MCO is emerging as a viable clinical planning option for reducing inter-planner
variations in plan quality, its overall dosimetric advantages versus traditional inverse planning remain
inconclusive. The conversion of a navigated fluence-based dose distribution into a deliverable plan
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can also degrade plan quality.30 However, this effect is correlated with plan complexity and
investigators have been working on multi-criteria direct-aperture optimization and other methods to
maximally reduce this conversion error.31-33 MCO’s other limitations are its limited commercial
availability and substantial computational cost, especially for cases requiring a large amount of tradeoff objectives (e.g. head-and-neck cancer).34,35
1.1.3

KNOWLEDGE-BASED PLANNING
An alternative method proposed to reduce inter-planner variations in inversely optimized

plan quality is knowledge-based planning (KBP). KBP methods have recently been introduced as a
means of improving plan quality and consistency by leveraging anatomical and dosimetric data from
previously treated patients to guide the planner in designing a plan for a new patient.
Knowledge-based concepts have been researched in many aspects of radiation oncology
such as imaging informatics and segmentation.36-39 However, KBP has become a main area of
interest due to its potential applications in many aspects of the treatment planning process. For
instance, KBP models have been used to predict patient-specific dose-volume objectives (based on
the available previous knowledge) before inverse optimization. Chanyavanich et al. used such an
approach with an algorithm based on mutual information to retrospectively predict prostate IMRT
plans that were dosimetrically similar to the original clinical plans.40 KBP models can also serve as
post-planning quality control tools by flagging patient plans where lower OAR dose is predicted
based on previous patient data. Wu et al. developed a quality control model to flag parotids planned
with too high a dose in IMRT head-and-neck cases.41 Also, KBP methods have been used in
exploring the feasibility of automated planning systems that require no human intervention. Tol et al.
recently assessed the ability of RapidPlan, Varian’s commercial knowledge-based planning module,
to automate plan quality assurance for clinical trials.42 The possibility of achieving fully automated
clinical treatment planning within the next ten years was recently debated.43 If this goal is to be
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realized at any point in the future, let alone in ten years, KBP research may be important in its
development and implementation.
In a general KBP dose prediction model, a database of previously treated patients with highquality treatment plans is established. Then for a new patient (to be planned), the database is
searched for a subset of prior patients with similar anatomy to the new patient. The dose data from
those anatomically similar database patients are then used to predict dose-volume objectives for the
new patient’s plan. This KBP method provides empirical dose predictions based on the patient’s
unique anatomy. This kind of patient-specific a priori information is not present in the current
clinical planning paradigm, where population-based dose tolerances for OARs are typically applied
as planning constraints. Moreover, a KBP model can explicitly predict personalized DVH objectives
or dose-volumes for new patients using previous patient data.
Several approaches to KBP have been described in the literature. Appenzoller et al. proposed
a KBP method using mathematical models to predict achievable OAR DVHs based on patient
anatomy to reduce IMRT planning variability and improve treatment plan quality.44 They separated
each OAR into sub-volumes based on the distance a collective group of voxels was away from the
planning target volume (PTV) surface. Then all sub-DVHs (DVHs of the individual sub-volumes)
were fitted to skew-normal distributions, which were used to predict DVHs. This predictive DVH
model has been successfully used in quality control studies for IMRT planning.23,45 Shiraishi et al.
further adapted this methodology to predict DVHs and identify sub-optimal plans for stereotactic
radiosurgery (SRS) cases.46 Good et al. developed a KBP model to predict dose for 7-field IMRT
prostate plans based on the mutual information between the beam’s-eye-view projections of a new
patient and database patients. They found the KBP plans to have superior (i.e. lower) bladder and
rectum DVHs compared to original clinical plan in 40% of cases.47 Moore et al. observed increased
normal tissue sparing and reduced inter-planner variability in IMRT prostate and head-and-neck
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cases after implementing a KBP model that correlated OAR volume overlapping the PTV with
mean OAR dose.48 Principal component analysis (PCA) based KBP models have also been used to
investigate how anatomical and dosimetric features affect OAR dose in prostate and head-and-neck
patients for DVH prediction purposes.49-52 Varian’s commercial KBP optimization engine RapidPlan
(Varian Medical Systems, Palo Alto, CA, USA) uses a combination of PCA and regression models to
estimate DVH predictions.53 Nwankwo et al. developed an algorithm that predicted dose to each
OAR voxel in VMAT plans of prostate patients by learning OAR sparing patterns from a database
of previous clinical plans.54 Similarly, Shiraishi et al. used previously treated VMAT prostate and SRS
head-and-neck plans to train an artificial neural network to predict patient-specific dose matrices for
new cases.55 Each of these studies aims to simultaneously improve plan quality and reduce plan
variability regardless of changing patient and planning variables.
1.1.4

THE OVERLAP VOLUME HISTOGRAM IN KBP
The quality of a treatment plan depends primarily on patient anatomy, particularly the

geometrical relationship between PTVs and OARs. Using mathematical phantoms, Hunt et al.
showed that PTV uniformity and maximum OAR dose depend strongly on PTV-OAR geometry,
specifically the distances between them.56 They also performed a separate study that showed a
correlation between the OAR volume overlapping the PTV and OAR sparing in head-and-neck
cases.57 Similarly, studies on examining prostate cancer have shown an increase in rectum and
bladder dose as prostate and seminal vesicle volumes increase.58
The investigations on anatomical influence on dosimetric outcomes have led to several novel
metrics relating patient anatomy to dose prediction. One common metric used in KBP DVH
prediction models to correlate patient geometry to OAR dose is called the overlap volume histogram
(OVH). Introduced by Kazhdan et al., the OVH is a shape relationship descriptor that quantifies a
patient’s anatomy by defining the distance a fractional OAR volume lies from the PTV surface.
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More specifically, it is defined for a target T and organ O, where the value of the OVH of O with
respect to T at distance r is defined as the fractional organ volume a distance of r or less from the
target:
𝑂𝑉𝐻$,& 𝑟 =

)∈$|,(),&)/0
$

,

(1.1)

where d(p,T) is the signed distance of a point p from the target’s boundary and |O| is the volume of
the OAR.59
The clinical viability of OVH-driven quality control tools and KBP methods have been
investigated due to the metric’s robustness and ease of clinical implementation. Wu et al. used the
OVH within a KBP method as an anatomical similarity metric for matching a new patient to
previous IMRT head-and-neck patients in a database. Their OVH-driven KBP model predicted
DVH objectives for the new patients, which led to significant decreases in planning time and dose to
the spinal cord, brainstem, and contralateral parotid.60 They have also shown the effectiveness of
KBP methods utilizing the OVH in improving the quality, efficiency, and consistency of
simultaneous integrated boosted-IMRT and VMAT planning for head-and-neck cancer.61,62 Further,
they have adapted their OVH-driven KBP methodology for robotic stereotactic body radiotherapy
(SBRT) and were able to improve bladder and rectum sparing in prostate cases.63 Likewise, Zhu et al.
introduced the distance-to-target histogram (DTH) as a metric to estimate OAR DVHs to improve
IMRT plan quality.49 The DTH is virtually identical to the OVH, but Zhu et al. differentiate their
DTH by incorporating non-Euclidean distance metrics.64
All OVH-driven KBP methods assume that the dose received by a fractional OAR volume
depends on its proximity to the PTV, which is described quantitatively by the OVH. Therefore, each
point on an OAR’s OVH can be mapped to one point on the corresponding DVH, establishing a
one-to-one relationship for each OAR of each database patient. This one-to-one distance-to-dose
mapping can be formed by relating a distance rv of an OVH for a fractional OAR volume v to a
12

dose-volume Dv of a DVH (Figure 4). This serves as the foundation of using the OVH as an
anatomical similarity metric in a KBP model for predicting DVH dose-volumes. Further, the simple
yet powerful nature of the OVH makes it a desirable metric to relate patient anatomical features to
optimally achievable dose distributions in KBP methods.

Figure 4: Illustration from Wu et al. relating the distance a fractional OAR volume (v) lies from the
PTV surface (rv) on the OVH (left) to the dose the fractional volume receives (Dv) on the DVH
(right).63
1.2

MOTIVATION FOR RESEARCH
Many of the previous studies have concluded that the performance or accuracy of a

particular KBP model depends directly on the quality of the plans in the patient database.60,65-69
These original database plans in a majority of KBP studies were created via inverse planning, which
means the KBP models are still subject to the same deficiencies of inverse planning. Recognizing
this, Schmidt et al. utilized dose warping and scaling reduce the impact of sub-optimal inverse plans
on the performance on their mutual information-based KBP model.66 Sub-optimal clinical plans are
difficult to detect due to the substantial time and labor involved in fully assessing clinical trade-offs
through the trial-and-error process of inverse optimization. Plan quality fluctuations can also result
from varying planning priorities from patient-to-patient and planner-to-planner (or physician-tophysician). In fact, Wang et al. recently used an in-house TPS to evaluate the performance of an
OVH-driven KBP method based on Pareto optimal treatment plans for prostate cases, independent
of these non-uniform treatment planning priorities.69 They found the OVH model was highly
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accurate in predicting rectum and anus dose, but systematically underestimated achievable bladder
dose likely due to the bladder’s lower planning priority relative to the rectum. However, the potential
improvements in OVH-driven KBP performance utilizing a plan database with uniform planning
priorities and void of sub-optimal inverse plans have not been examined to our knowledge.
KBP’s susceptibility to planner bias and plan variations can be avoided through the use of
MCO at the cost of computational burden. Therefore, the purpose of this study was to investigate
the performance of a MCO-driven KBP planning approach as an efficient solution. Specifically, this
work examined OVH-driven KBP dose-volume prediction dependence on database plan quality for
VMAT treatment planning of the prostate. The study compared the use of a database containing
manual, inversely optimized clinical plans (referred to as the CPD – clinical plan database) against a
database of plans generated with MCO (referred to as the MCOD). Two sets of OVH-driven KBP
dose-volume predictions for the bladder and rectum were generated: one set derived from the
original clinical plan data (CPD) and the other set derived from the Pareto optimal plan data
(MCOD). The optimality of the two sets of predictions were compared and their achievability was
verified through a re-planning study.
1.3

HYPOTHESIS AND SPECIFIC AIMS
The hypothesis of this work was that OVH-driven KBP predictions using a MCO plan

database (MCOD) will lead to plans with statistically significant improvements (p < 0.017) in bladder
and rectum dose while maintaining statistically equivalent or superior target and secondary OAR
(femoral heads and penile bulb) dose, compared with using a clinical plan database (CPD). In order
to test this hypothesis, three specific aims were developed for this study:
Aim 1: Establish a retrospective anonymous patient database; compile the OVH, CPD, and
MCOD knowledge databases; investigate second-order factors influencing the
distance-to-dose correlation strength while accounting for inter-planner variability.
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Aim 2: Develop and apply OVH-driven KBP model for predicting bladder and rectum
dose-volumes using each plan database; statistically analyze any dosimetric
differences between CPD and MCOD KBP model predictions.
Aim 3: Perform a re-planning study by applying KBP dose-volume predictions as planning
goals; statistically analyze differences between re-planned and predicted KBP model
values to verify the achievability of KBP model predictions.
1.4

OVERVIEW OF THESIS
This document follows a manuscript-style thesis format. The introductory Chapter 1

contains background information for the entire study and establishes the motivation and central
themes of this research. Chapter 2 and Chapter 3 mirror two separate manuscripts respectively
prepared for submission to peer-reviewed scientific journals, of which the former has been
submitted for peer-review at the time of writing this thesis. These two chapters contain their own
materials and methods, results, discussion, and conclusions sections. Background and introductory
information for both manuscript chapters were consolidated into Chapter 1 to avoid redundancies.
Chapter 4 summarizes the overall findings of the study and discusses limitations and directions for
future work. This thesis contains only one References section (again to avoid redundancies) and
each cited work is listed in the order in which they appear in the document. Lastly, the Appendix
contains extraneous methods and supplementary data either not mentioned or implicitly mentioned
in the materials and methods sections of the thesis.
Generally, the specific aims laid out in Chapter 1.3 are addressed chronologically in this
thesis. In other words, if aligning the specific aims to specific chapters, Aim 1 is contained in
Chapter 2 while Aims 2 and 3 are contained in Chapter 3. However, certain aspects of the specific
aims are inherently present in both manuscript chapters.
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CHAPTER 2. AN IMPROVED DISTANCE-TO-DOSE CORRELATION
FOR PREDICTING BLADDER AND RECTUM DOSE-VOLUMES IN
KNOWLEDGE-BASED VMAT PLANNING FOR PROSTATE CANCER
2.1

MATERIALS AND METHODS

2.1.1

PATIENT DATABASE
We developed a database, compliant with the Health Insurance Portability and

Accountability Act (HIPAA), of 124 prostate cancer patients previously treated at Mary Bird Perkins
Cancer Center. Selected patients were prescribed dose to a single PTV and treated using two
coplanar, 6 MV VMAT beam arcs. Patients with artificial hip prostheses, where beams are
prohibited from entering through the implant, and patients with sequential boosts were excluded.
Selected patients included those having post-operative prostate fossa, seminal vesicle involvement,
and pelvic lymph node involvement where only a single PTV was irradiated. A statistical summary of
the resulting patient database is shown in Table 1.
All patients in the database had an existing treatment plan that had been manually optimized
by different planners using the commercial TPS currently used clinically at our institution (Pinnacle3,
v9.8, Philips Medical Systems, Hanover, WI, USA). For the purpose of the present study, it was
desirable to reduce planner-to-planner variability. Accordingly, all database patients were re-planned
with a different commercial TPS with available tools for minimizing inter-planner variability
(RayStation, v4.5.1.14, RaySearch Laboratories, Stockholm, Sweden).
Specifically, re-plans were objectively generated for each database patient using MCO. As
mentioned previously, MCO is a novel optimization algorithm based on a combination of Pareto
optimal plans generated from user-specified trade-off objectives and constraints. Pareto optimal
plans are those where the constraints are computationally feasible and no objective can be improved
without worsening another. In the TPS, a “balanced plan” is the Pareto plan giving equal weight to
all objectives.24 Previous studies have indicated MCO can provide superior plan quality and planning
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Table 1: Distribution of patient characteristics in the database. The selected patients cover a wide
range of prescription doses, treatment areas, and target volumes. SV stands for seminal vesicle
involvement and LN stands for lymph node involvement.
Prescription
Number of Patients
Dose Range (cGy)
4500 - 7000
38
7000 - 7600
43
7600 - 8100
33
8100
10
Treatment Area
Prostate Only
66
Prostate Fossa
23
Prostate + SV
Or
35
Prostate + SV + LN
PTV Volume
Range (cm3)
69 - 150
22
150 - 225
56
225 - 300
19
300 - 729
27
efficiency compared to traditional inverse planning.26,29 Therefore, the MCO balance plan for each
patient was used to maximize both plan consistency and quality. Each MCO plan was created to
match the previous prescription dose using a standard set of trade-off objectives and constraints,
which produced consistent Pareto optimal dose distributions (Table 2). In order to account for
patients with different prescription doses, the dose for each patient was normalized such that 95%
of the PTV received 7600 cGy. It is important to note the effects of this scaling were examined and
found to have no measurable impact on the dose distributions, allowing for inter-plan comparisons.
The scripting feature in RayStation was leveraged to automate the computation of bladder
and rectum OVHs for each database patient by uniformly contracting or expanding the PTV in 1
mm step sizes. This OVH data was used to describe the PTV-OAR geometrical information of the
database patients.
To determine the strength of the distance-to-dose relationship for 30, 50, 65, and 80%
bladder and rectum dose-volumes of database patients, the correlations between database OVHs
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and DVHs for those specific bladder or rectum dose-volumes were calculated using the Pearson
product-moment correlation coefficient (R).
Table 2: MCO planning objectives and constraints used in generating balance plans for each
database patient. The Dose Fall-off objective for the External structure reduces dose outside of the
target. Rx refers to the prescription dose.
Trade-off Objectives
Constraints
Structure
(cGy)
(cGy)
Min Dose = Rx
PTV
Uniform Dose = Rx
Max Dose = Rx + 100
Bladder
Max EUD = 0, (a=2)
Rectum
Max EUD = 0, (a=2)
Left and Right
Max EUD = 0, (a=2)
Femoral Heads
Penile Bulb
Max EUD = 0, (a=2)
Dose Fall-off = [H] 3000 [L] 0,
External
Low Dose Distance = 5 cm
2.1.2

SECOND-ORDER FACTORS
An array of dosimetric and anatomical second-order factors were chosen to examine for

correlation with OAR dose. These factors included the derivative of the OVH (dOVH), prescription
dose, PTV volume, bladder volume, rectum volume, and in-field OAR volume. The dOVH
quantifies the specific orientation of the OAR relative to the PTV, where a higher dOVH value
describes an OAR likely more difficult to spare than one with a lower dOVH. For example, it is
possible for equal fractional OAR volumes in two different patients to have similar OVH distances,
but have differing dOVH values that could lead to a difference in the dose each volume receives. Infield OAR volume was defined as the amount of OAR volume that lies within transverse planes
located 6 mm (approximating the beam penumbra at depth) superior and inferior to the most
superior and inferior aspects of the PTV respectively.
The ability of each second-order term to strengthen distance-to-dose correlations was
quantified by computing the Pearson product-moment correlation coefficient (R). This coefficient
was calculated for each factor and OAR dose-volume pair over each of the four fractional bladder
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and rectum volumes previously listed in Chapter 2.1.1. The resulting correlation coefficients were
averaged over the four fractional volumes for each OAR. The second-order factor with the
strongest mean correlation with OAR dose was determined to be the strongest contributor to the
DVH-OVH correlation variation for the given OAR.
2.1.3

IMPROVED DISTANCE-TO-DOSE CORRELATION
After the factor with the strongest effect on the distance-to-dose correlation variation was

determined for the bladder and rectum, the DVH-OVH correlations were recomputed while
including the second-order factor. These improved (OVH plus second-order term) correlations were
compared to the nominal (OVH only) correlations to quantify any improvements in the database
distance-to-dose correlations.
As will be shown in the Results section, the in-field OAR volume was found to be the
strongest contributor to variations in correlation between distance and dose for both the bladder
and the rectum. As such, the OVH was also recomputed by disregarding out-of-field volume.
Described by Petit et al., the in-field OVH is calculated similarly to the total OVH except only the infield OAR volume is considered when determining the overlapping OAR volume with the
contracted or expanded target volume.65 This introduces a slight modification to Equation (1.1):
𝑂𝑉𝐻$,& 𝑟 =

𝑝 ∈ 𝑂2 |𝑑(𝑝, 𝑇) ≤ 𝑟
𝑂

(2.1)

where O’ is the portion of the organ O within the treatment fields (defined previously). The
computational endpoint for the in-field OVH of a given OAR is when the PTV is expanded to
overlap the entire in-field portion of the OAR’s volume. Further, the in-field OVH distance for
100% overlap volume exists only when the entire OAR is within the defined treatment fields.
Therefore, those patients in the database with fractional in-field OAR volumes less than the selected
dose-volume value will not contribute to forming the dose-to-distance correlation. For example, if
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only 67% of the bladder is within the treatment fields for a particular database patient, then that
patient will not be included when calculating the correlation between the 80% dose-volume and the
in-field OVH.
2.2

RESULTS

2.2.1

NOMINAL DVH-OVH CORRELATION
Using the nominal OVH to quantify anatomy, the DVH-OVH correlation showed a

negatively linear relationship in both OARs for each fractional volume observed. Bladder dose
showed a strong anticorrelation with distance, having a mean R = -0.79 over the four fractional
volumes analyzed. Rectum dose also showed a strong anticorrelation with distance, having a mean
R = -0.82 (Table 3). Figure 5 shows each nominal DVH-OVH scatter plot associated with each
Pearson correlation coefficient listed in Table 3.
Table 3: Pearson correlation coefficients between nominal OVH distances and DVH dose-volumes
of the bladder and rectum. An absolute value greater than 0.7 indicates a strong linear correlation
with a maximum value of 1.
Dose-Volume DVH-OVH R
Bladder
D30
-0.92
D50
-0.83
D65
-0.74
D80
-0.66
Mean
-0.79
Rectum
D30
-0.94
D50
-0.86
D65
-0.78
D80
-0.70
Mean
-0.82
The variation in distance-to-dose correlation across patients can be seen in Figure 5. For
example, the reader is directed to the DVH-OVH plot for 65% of the rectum (Figure 5 (f)), where
the range of D65 for an OVH distance of 2 cm was 643 to 3011 cGy. This spread in dose of greater
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than 2300 cGy for a given OVH distance is consistent with previous studies and illustrates the
motivation of the present study.52,63,70

(a)

(b)

(c)

(d)

Figure 5: Nominal DVH-OVH correlations for 30, 50, 65, and 80% dose-volumes of the bladder (a,
c, e, g) and rectum (b, d, f, h).
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(Figure 5 continued)

(e)

(f)

3011 cGy

643 cGy

(g)

2.2.2

(h)

SECOND-ORDER FACTORS
Each previously investigated second-order factor was introduced as a variable into the

nominal DVH-OVH correlation for each fractional volume of the bladder and rectum via a color
bar. The variables were visually inspected via these color bar scatter plots to assess relational
dependence between the second-order factors and dose for the fractional OAR volumes. Of all the
factors studied, only the in-field OAR volume showed any noticeable influence on OAR dose, as
seen in Figure 6 (c) and (d). The data indicated that, as the in-field OAR volume increases, the dosevolume value for the associated OAR also increases. This trend was observed in all scatter plots for
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every fractional volume DVH-OVH of the bladder and the rectum. For the other factors
investigated, no such trends were noted (see Figure 6 (a) and (b)).

(a)

(b)

(c)

(d)

Figure 6: Sample color scatter plots for qualitative review of dependence on the examined secondorder factors. There is no visible relationship between dose and PTV volume for neither 65% of the
bladder (a) nor the rectum (b). When analyzing in-field OAR volume however, a clear relationship
with D65 for the bladder (c) and rectum (d) can be seen.
Pearson correlation coefficients between second-order factors and bladder and rectum dosevolumes are listed in Table 4. Of the six variables inspected, only in-field OAR volume showed a
strong correlation with OAR dose for both the bladder (mean R = 0.86) and the rectum (mean R =
0.76). The in-field OAR volume had a correlation coefficient of greater than 0.7 for each bladder
and rectum dose-volume, except for D30 of the rectum. While the dOVH was strongly correlated
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with D30 (R = 0.75) and D50 (R = 0.74) of the rectum, the in-field OAR volume resulted in a
stronger correlation with rectum dose overall. This indicates in-field OAR volume had the strongest
correlation with OAR dose out of the evaluated factors, confirming the qualitative indications.
Table 4: Pearson correlation coefficients between each second-order factor and DVH dose-volumes
for the bladder and rectum. The mean Pearson coefficient over the four fractional volumes is also
listed. Only the in-field OAR volume was strongly correlated (mean greater than 0.7) for both the
bladder and rectum.
Rx
PTV
Bladder Rectum In-field OAR
Dose-Volume dOVH
Dose Volume Volume Volume
Volume
Bladder
D30
0.62
-0.44
0.50
-0.53
0.20
0.90
D50
0.56
-0.41
0.41
-0.55
0.19
0.88
D65
0.52
-0.41
0.39
-0.52
0.17
0.85
D80
0.48
-0.43
0.38
-0.53
0.18
0.83
Mean
0.54
-0.42
0.42
-0.53
0.19
0.86
Rectum
D30
0.75
-0.60
0.77
0.16
-0.11
0.56
D50
0.74
-0.49
0.67
0.05
-0.07
0.74
D65
0.67
-0.43
0.56
-0.07
-0.02
0.87
D80
0.55
-0.53
0.60
-0.11
-0.09
0.85
Mean
0.68
-0.51
0.65
< 0.01
-0.05
0.76
2.2.3

IMPROVED DVH-OVH CORRELATION
The distance-to-dose correlation showed improvement when the in-field OAR volume was

accounted for in the computation of the OVH (Table 5). For the bladder, the in-field OVH
strengthened the mean correlation coefficient from -0.79 to -0.85 over the four fractional volumes.
While for the rectum, the mean correlation strengthened from -0.82 to -0.86. This increase in
correlation strength was especially noticeable at the 80% fractional volume level for both the bladder
and rectum, where the 80% bladder DVH-OVH R strengthened from -0.66 to -0.77 and the value
for 80% rectum improved from -0.70 to -0.86.
An illustrative example of the differences between the DVH-OVH correlations using the
nominal OVH versus the in-field OVH can be seen in Figure 7. Accounting for the in-field OAR
volume in the OVH computation resulted in an improvement in the distance-to-dose correlation for
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65% and 80% of the bladder (Figure 7 (a) and (c) respectively) and rectum (Figure 7 (b) and (d)
respectively). It is important to reiterate that the decrease in data points for the higher fractional infield OAR volumes is due to certain database patients not meeting the given in-field OAR volume
threshold.
Table 5: Pearson correlation coefficients between in-field OVH distances and DVH dose-volumes
of the bladder and rectum. The correlation coefficients between the nominal OVH distances and
DVH dose-volumes from Table 3 are also listed for comparison. Note that n refers to the number
of database patients with in-field OAR volumes greater than or equal to the given dose-volume.
DVH-OVH R
Dose-Volume Nominal OVH In-field OVH
Bladder
D30
-0.92
-0.91 (n = 108)
D50
-0.83
-0.88 (n = 76)
D65
-0.74
-0.85 (n = 52)
D80
-0.66
-0.77 (n = 35)
Mean
-0.79
-0.85
Rectum
D30
-0.94
-0.93 (n = 124)
D50
-0.86
-0.84 (n = 117)
D65
-0.78
-0.82 (n = 90)
D80
-0.70
-0.86 (n = 49)
Mean
-0.82
-0.86
With regards to the representative example of the distance-to-dose correlation variation at
65% of the rectum introduced earlier (referencing Figure 5 (f)), Figure 7 (b) shows the reduction in
the dose spread at an OVH distance of 2 cm from using the in-field OVH method. The group of
patients with rectum D65 less than 10 Gy have very low doses to the rectum, most likely due to
having less than 65% of the rectum inside the treatment fields. The removal of these patients using
the in-field OVH term reduces the dose spread at the OVH distance of 2 cm from over 20 Gy with
the nominal OVH method to less than 10 Gy.
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(a)

(b)
In-field OVH
Variation
Nominal OVH
Variation

(c)

(d)

Figure 7: Representative examples of improved distance-to-dose correlations using the in-field OVH
compared with the nominal OVH. The figure legends contain the number of patients (n) and the
Pearson correlation coefficients (R) for each OVH method. The square nominal OVH data points
are equivalent to the scatter plots shown in Figure 5.
2.3

DISCUSSION
In-field OAR volume was observed to be the largest contributor to variations in the

distance-to-dose relationship for fractional overlap volumes of bladder and rectum in prostate
patients treated with VMAT, independent of inter-planner bias. Specifically accounting for OAR
volume within the treatment fields when computing the OVH strengthened the OVH’s correlation
with the bladder and rectum dose in these patients. This proposed OVH refinement eliminates data
points that would likely produce unachievable dose predictions in an OVH-guided KBP tool. This
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was evidenced by the consistent removal of a large portion of low-dose data points, which facilitated
the strengthening of the distance-to-dose correlations. This was seen most clearly for the lower
dose-volumes of both OARs e.g. D65 and D80 shown in Figure 7. Therefore, determining in-field
OAR volume as an influencing factor in the DVH-OVH correlation, and accounting for this
through the in-field OVH, will allow for more achievable and accurate dose predictions for OVHguided KBP models.
Previous studies have refined OVH-guided KBP methods for different treatment sites to
generate more precise planning predictions without fully quantifying the resulting effects on the
distance-to-dose correlation used to estimate the DVH objectives. Reddy et al. found prostate
volume was directly proportional to bladder and rectum dose in 3D-CRT and IMRT plans.58
Similarly, Wu et al. implemented an empirical PTV volume filter, querying a patient database for a
subset of patients with specific OVH values and similar PTV volumes for their KBP method for
localized prostate patients treated with robotic SBRT.63 This work shows PTV volume to be
moderately correlated with bladder dose (mean R = 0.42) and rectum dose (mean R = 0.65), which
validates PTV volume as a simple, yet viable second-order factor when predicting bladder and
rectum dose-volumes for OVH-guided KBP methods for prostate patients. However, our work also
shows that filtering patients based on in-field bladder and rectum volume and even dOVH would
provide an even stronger distance-to-dose model compared to using PTV volume, resulting in more
robust dose-volume predictions. While in-field OAR volume may not be as easily defined for
robotic SBRT as with VMAT treatments given the multitude of non-coplanar and non-isocentric
beams, the relationship between OAR dose and in-field volume should hold across different
treatment techniques.
This work also confirms and builds upon the findings by Petit et al., who demonstrated that
utilizing the in-field OVH will result in more accurate and fewer unachievable dose predictions for
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cases with sizable portions of nearby OARs lying outside the treatment fields.65 While their group
analyzed the in-field OVH’s effects with pancreatic adenocarcinoma patients treated with IMRT, our
similar findings with VMAT prostate cases support the in-field OVH’s efficacy in OVH-guided
KBP methods in any treatment site. A novel component of our study is the reduction of interplanner variability through the generation and implementation of a Pareto optimal plan database.
Even with this decrease in inter-planner subjectivity, the in-field OAR volume was still found to be
the strongest second-order factor correlating with OAR dose in these standardized plans. Another
noted difference between these two studies is the definition of in-field volumes. Petit et al. defined a
1 cm margin around the beams-eye-view of the PTV as the field edges, where we defined our infield transverse plans to be 0.6 cm superior and inferior of the most superior and inferior aspects of
the PTV. Differences in results depending on in-field volume definitions would require further
analysis. Regardless, our results support the claim that accounting for in-field OAR volume will lead
to more precise and accurate OVH-driven KBP dose predictions.
Additionally, this study supplements the results reported by Yuan et al., who analyzed factors
impacting interpatient OAR dose sparing. While they used a stepwise multiple regression model on
prostate and head-and-neck IMRT treatments, out-of-field OAR volume (converse to in-field
volume) was found to be a significant factor in determining OAR dose sparing.52 It should also be
noted this group utilized a non-Euclidean form of the OVH to account for voxels outside treatment
fields to form their distance-to-dose correlation, resulting in a reduction in the correlation variation.
Our work shows a similar reduction in distance-to-dose correlation spread using the in-field OVH.
This study presents a comprehensive analysis and review of second-order factors potentially
influencing the distance-to-dose relationship, which serves as the foundation for OVH-driven KBP
dose prediction methods. As opposed to previous studies using patient cohorts with uniform beam
configurations, dose prescriptions, and disease types, this work analyzes distance-to-dose correlation
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behavior in a large patient database with a wide range of treatment parameters and structure volume
sizes. Another feature unique to this work, that must be reiterated, was the implementation of an
objective and standardized MCO planning protocol applied to each of the 124 database patients.
This served to maximally reduce plan quality variations from patient to patient due to the inherent
subjectivity and inconsistencies from inverse treatment planning and inter-planner variations. The
composite impact of these factors was inspected over the low-, medium-, and high-dose levels of the
OAR DVHs, capturing the overall influence each factor has on the distance-to-dose correlation.
These results indicate an improvement in the distance-to-dose correlation, which can be
implemented in existing OVH-guided KBP dose prediction tools by recalculating the OVH based
on in-field OAR volume. While this reduction in the DVH-OVH correlation variation should lead
directly to more accurate and less unachievable predictions in a prostate KBP protocol, a
comprehensive retrospective study needs to be performed to confirm this conclusion. However, this
study was primarily focused on how second-order factors impacted the distance-to-dose relationship
in prostate patients treated with VMAT. Although knowledge from this and previous studies
indicate in-field OVH strengthening the DVH-OVH correlation should generalize to other
treatment sites, site-specific investigations are needed to support implementation of the in-field
OVH.
Although the in-field OVH demonstrated a reduction in distance-to-dose correlation spread,
further study is needed to investigate how accounting for moderately influencing factors (such as the
dOVH) would affect this spread. Further, these models could be applied in an existing OVH-guided
KBP dose prediction tool and a study could be performed to quantify and compare the accuracy and
achievability of the predictions generated from the unadjusted and adjusted distance-to-dose
correlations.
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2.4

CONCLUSIONS
This work shows the use of the OVH in KBP methods can be improved by accounting for

in-field OAR volume. Planner bias was minimized by objectively generating Pareto optimal VMAT
plans for each prostate patient in a large, retrospective database. This facilitated the examination of
non-systematic contributors or second-order factors affecting inter-plan variability. Out of the
various treatment and patient parameters investigated, in-field OAR volume was found to correlate
strongest with OAR dose for both the bladder and rectum. Also, the dOVH was found to be the
next strongest correlating factor with both bladder and rectum doses, while rectum volume
correlated least with bladder dose and bladder volume correlated least with rectum volume.
Differences in prescription dose and PTV volume were found to be moderately correlated with
bladder and rectum doses. The incorporation of the in-field volume into the OVH showed a
reduction in distance-to-dose correlation variation, which can lead to more precise and achievable
dose predictions in KBP methods.

30

CHAPTER 3. USING THE BEST KNOWLEDGE: IMPROVED
KNOWLEDGE-BASED DOSE PREDICTIONS IN VMAT PLANNING
FOR PROSTATE CANCER BY USING A PARETO PLAN DATABASE
3.1

MATERIALS AND METHODS

3.1.1

PATIENT DATABASE
A HIPAA-compliant database of 124 prostate cancer patients previously treated at our

institution was created for this study. Selected patients had only one PTV and were treated with two
coplanar 6 MV VMAT arcs. Patients with artificial hip implants were excluded due to the reduction
in degrees of freedom of the treatment arc. Additionally, patients with a sequential boost to a subvolume of the initial PTV were excluded. However, post-operative prostate fossa patients were
included, as were patients with seminal vesicle and lymph node involvement so long as only one
PTV was defined (Table 1). In order to compare patient plans with differing prescription doses, each
patient’s dose was normalized so that 95% of the PTV received 76 Gy.
3.1.2

KNOWLEDGE DATABASES
The DICOM image set, structure, plan and dose files of all 124 selected database patients

were imported into a research database of a commercial TPS (RayStation v4.5.1.14, RaySearch
Laboratories, Stockholm, Sweden). Anatomical and dosimetric knowledge databases were then
compiled.
The clinical viability of the OVH as a feature metric in KBP methods has been tested due to
the metric’s robustness and simple clinical implementation.60-63 Early research into the effectiveness
of the OVH for sites with large OARs extending outside the treatment fields has demonstrated the
potential advantages of accounting for the out-of-field OAR volumes through the OVH.52,65 This
can be done through the in-field OVH, which modifies the standard OVH to include the OAR
volume only within the treatment fields. Compared to the standard OVH, we have observed the infield OVH to improve the distance-to-dose correlation for bladder and rectum dose-volumes in
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VMAT prostate cases independent of planner-bias. Therefore, the in-field OVH metric was used to
quantify the anatomical information of each database patient.
A custom script supported by the TPS (IronPython, Apache) was written to calculate the infield OVH for each patient’s bladder and rectum. The in-field OVH was computed by expanding
and contracting the PTV in 1 mm increments until there was either complete overlap or no overlap
with the in-field portion of the given OAR. In this study, “in-field” was defined as the volume
extending laterally to the external patient surface and longitudinally between planes located 6 mm
superior and 6 mm inferior to the edges of the PTV. The value of 6 mm was chosen to approximate
the penumbra of the treatment fields.
To establish the clinical plan database (CPD), a separate script was developed to extract the
dose volume histogram (DVH) data from each patient clinical treatment plan. The DVHs of the
PTV, bladder, rectum, femoral heads, and penile bulb (if segmented) for each patient were extracted
from the TPS and placed in a repository which, along with the anatomic information, formed the
CPD. Here, the bladder and rectum will be referred to as the primary OARs and the femoral heads
and penile bulb as secondary OARs.
For the creation of the MCO database (MCOD), each database patient was re-planned using
MCO functionality available within the TPS and using the original DICOM image and structure sets
of the patient. In the TPS, a Pareto plan is generated for each of the user-defined objectives, with
each plan fully optimized for that specific objective. An additional Pareto plan, called the “balance
plan,” is created with each of the trade-off objectives weighted equally. The user is then able to
dynamically navigate over a linear combination of these plans (i.e. the Pareto surface) to assess
different clinical trade-offs in search of a desired solution for the specific patient. In this study, each
MCO plan was optimized with a standard set of prescription-specific trade-off objectives and
constraints (Table 2). After the generation of the Pareto plan databases were completed for each
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patient, a script was written to extract DVHs from each patient’s balance plan. These dose data were
placed into a different repository which, along with the same anatomic information used with the
CPD, formed the MCOD.
3.1.3

KBP PREDICTIONS AND ANALYSIS
A KBP method of predicting dose-volumes for the rectum and bladder using the in-field

OVH was developed for this study. The process generally follows the methodology described by Wu
et al. and is briefly described here.60
The fundamental assumption of the approach is that the dose received by a fractional OAR
volume depends on its proximity to the PTV, which is described quantitatively by the in-field OVH.
Therefore, each point on an OAR’s in-field OVH can be mapped to one point on the corresponding
DVH, establishing a one-to-one relationship for each OAR of each database patient. This in-field
OVH to DVH mapping, in turn, allows the DVH of a new patient to be predicted from database
patients queried to have similar OAR-PTV anatomy (i.e. in-field OVH values).
Mathematically, given a new patient n with an in-field OVH distance of rv,n for a specified
fractional OAR volume of v, the dose that fractional volume receives (Dv,n) can be estimated from a
knowledge database of i patients by:
D7,8 = min D7,< r7,< ≤ r7,8

(3.1)

The subset of database patients where 𝑟>,? ≤ 𝑟>,@ represents cases where the in-field OVH values
imply the fractional OAR volumes are at least as difficult to spare as the new patient’s geometry.
Dose-volumes were predicted for D10, D30, D50, D65, and D80 fractional volumes of bladder
and rectum. The dose-volume predictions were generated using a leave-one-out method, whereby
each patient was removed from the database and assumed to be the “new” patient for whom dosevolumes would be predicted with the 123 database patients that remained.71 This process was
repeated until predictions were made for each database patient. Two sets of dose-volume predictions
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were made for each database patient: one set using the CPD model and the other set using the
MCOD model. For the case where rv,n was less than rv,i for all i database patients, no dose prediction
was made. In this case, the newly introduced patient would have a fractional OAR volume closer to
the PTV than any patient in the database. So an achievable dose-volume prediction cannot be
accurately generated with the given knowledge. Also, given the nature of the in-field OVH,
predictions were not possible for patients with fractional in-field OAR volumes less than the desired
dose-volume prediction. For example, a prediction for a patient’s bladder D50 would not be possible
if less than 50% of that patient’s bladder was within the treatment fields.
For each of the five dose-volumes of both OARs, three distributions of dose-volumes were
compared: the set of original clinical values, the set of CPD KBP model predictions, and the set of
MCOD KBP model predictions. Differences between the three data sets were tested for statistical
significance using two-sided Wilcoxon signed-rank tests for each dose-volume. Statistical
significance was set at p = 0.017, which results from applying a Bonferroni correction of three to the
traditional significance level of 0.05.
3.1.4

PREDICTION PERFORMANCE AND ACHIEVABILITY
In order to confirm the achievability of KBP-predicted dose-volumes, 31 patients were

randomly selected from the original database and re-planned using inverse optimization with the
bladder and rectum KBP predictions as planning objectives. Because each patient had two sets of
KBP dose-volume predictions, the lowest dose-volume prediction between the CPD and MCOD
KBP models was used as the planning goal for each “new” patient. Again, bladder and rectum D10,
D30, D50, D65, and D80 dose-volumes were used for these re-planning goals.
Re-plans attempted to maintain similar PTV and secondary OAR dose compared the original
clinical plans while simultaneously aiming to attain the bladder and rectum KBP dose-volume
predictions. This was done in order to make an assessment of the clinical achievability of the
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predicted bladder and rectum KBP dose-volumes. Two-sided Wilcoxon signed-rank tests between
the bladder and rectum KBP dose-volume predictions and the re-planned values were used to
quantify prediction achievability. Two-sided Wilcoxon signed-rank tests were also used to verify the
re-plans maintained clinical PTV and secondary OAR dose. The significance level for these statistical
tests was set at p = 0.05. Various dose metrics were analyzed to compare PTV and secondary OAR
dose shown in Table 6. In this study, the homogeneity index (HI) and conformity index (CI) were
calculated according to their ICRU definitions:72,73
HI =
CI =

DC − DEF
DGH

treated volume
target volume

(3.2)

(3.3)

where the treated volume is defined in this study as the tissue volume that receives at least 95% of
the prescription dose.
Table 6: Dose metrics used to statistically verify clinical PTV and secondary OAR dose was
maintained in the re-plans. Vx represents the percent volume receiving x% of the prescription dose.
Planning Structure
Evaluated Dose Metrics
D2, D50, D98, Dmax, Dmean, Dmin,
PTV
V95, V98, V100, V107, HI, CI
Femoral Heads
D2, Dmax, Dmean
Penile Bulb
Dmean
3.2

RESULTS

3.2.1

DATABASE AND PREDICTION ANALYSIS
When comparing the DVHs from the two KBP plan databases, the MCOD showed better

PTV coverage, primary OAR sparing and secondary OAR sparing (Figure 8). On average over the
124 database patients, the MCOD plans improved PTV HI (p < 0.001) and CI (p < 0.001) compared
to the CPD plans. The MCOD plans yielded average decreases in Dmean of 21.9 Gy over both
femoral heads (p < 0.001) and 9.9 Gy for the penile bulb (p < 0.001) compared to the CPD plans.
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The MCOD plans also decreased the average Dmean of the bladder and rectum by 5.8 (p < 0.001) and
4.3 Gy (p < 0.001) respectively from the original clinical plans.

Figure 8: Comparison between the average DVHs of the labeled planning structures from plans in
the CPD (solid lines) and MCOD (dashed lines). Note: the femoral heads are plotted separately (i.e.
left and right femoral heads) but are difficult to resolve as they are nearly identical and their curves
overlap each other.
Figure 9 shows boxplots of differences in bladder and rectum dose-volumes from the
original clinical plans, the CPD KBP model predictions, and MCOD KBP model predictions. These
boxplots show how both KBP models compare with the original clinical values including how the
two KBP models compare with each other. When interpreting the plots in Figure 9, a positive value
for either of the first two boxes indicates the KBP model prediction was lower than the
corresponding clinical dose-volume. Additionally, positive values for the third box indicate the
MCOD model prediction was lower than the corresponding CPD model prediction.
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Both KBP models generated predictions with a lower median dose than the clinical plans for
all five bladder and all five rectum dose-volumes. The medians of the MCOD KBP dose predictions
were lower for all five bladder and three rectum dose-volume points compared to the corresponding
CPD KBP medians.
The results from the statistical analysis comparing the patient database dose-volumes from
the clinical plans, CPD KBP model, and MCOD KBP model are shown in Table 7. For each of the
five bladder and five rectum dose-volumes analyzed, both the CPD and MCOD KBP model
predicted statistically lower dose compared to the clinical plans (p < 0.001).

(a)

Figure 9: Set of boxplots showing differences in dose-volumes between the clinical plan values, the
CPD KBP model predictions, and MCOD KBP model predictions for the bladder (a) and the
rectum (b). Below each dose-volume lists the number of patients, n, where a KBP prediction was
possible under the protocol detailed in Chapter 3.1.3. Note: data points outside boxplot whiskers are
more than 1.5 times the interquartile range (first quartile to third quartile i.e. length of boxes) from
the first or third quartiles, the grey circles represent the mean of each distribution, and the horizontal
black lines within each box represent the median of each distribution.

37

(Figure 9 continued)

(b)

Bladder dose-volumes predicted from the CPD and MCOD models were on average 7.34 and 11.09
Gy lower than the clinical values respectively. As for the rectum, the predicted dose-volumes from
the CPD and MCOD models were on average 8.96 and 8.91 Gy less than the clinical plans
respectively.
When comparing the two KBP methods, the MCOD model predicted significantly lower
dose than the CPD model for all five bladder (p < 0.001) and two of the five rectum dose-volumes
(D50; p = 0.004 and D65; p < 0.001). The MCOD model bladder dose predictions were on average
3.75 Gy less than the CPD model predictions over the five dose-volumes. Whereas the MCOD
model predictions were on average 1.04 Gy less than the CPD model values of D50 and D65 for the
rectum. CPD model predictions of rectum D10 (p = 0.005) and D30 (p < 0.001) doses were
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statistically lower than the MCOD model. These predicted dose-volumes were on average 1.19 Gy
lower for the CPD model compared to the MCOD model.
Table 7: Statistical comparison of CPD and MCOD KBP model and clinical dose-volumes, with
associated mean differences between combinations of the clinical, CPD model, and MCOD model
dose values. These mean differences correspond to the grey circles in Figure 9.
Mean Differences (cGy)
Dose
Metric
Bladder
D10
D30
D50
D65
D80
Rectum
D10
D30
D50
D65
D80

N†

Clinical
–
CPD

Clinical
–
MCOD

CPD
–
MCOD

123
107
75
51
34

105.4
598.8
840.2
1043.8
1080.4

677.2
1199.8
1143.4
1189.6
1335.7

123
123
116
89
48

302.4
966.5
1211.5
1036.3
961.1

204.0
827.7
1262.5
1192.3
969.0

Two-sided Wilcoxon p-values
Clinical
vs.
CPD

Clinical
vs.
MCOD

CPD
vs.
MCOD

571.8
600.9
303.2
145.7
255.3

< 0.001*
< 0.001*
< 0.001*
< 0.001*
< 0.001*

< 0.001*
< 0.001*
< 0.001*
< 0.001*
< 0.001*

< 0.001*
< 0.001*
< 0.001*
< 0.001*
< 0.001*

-98.4
-138.8
51.0
156.0
7.8

< 0.001*
< 0.001*
< 0.001*
< 0.001*
< 0.001*

< 0.001*
< 0.001*
< 0.001*
< 0.001*
< 0.001*

0.005*
< 0.001*
0.004*
< 0.001*
0.049

*Indicates a statistically significant result of p < 0.017, which was Bonferroni corrected from 0.05
† N represents the number of database patients where an in-field OVH-driven KBP prediction was possible
i.e. predictions were not made for patients with fractional in-field OAR volumes less than the given dosevolume

3.2.2

KBP PREDICTION ACHIEVABILITY
Figure 10 shows the average PTV and secondary OAR DVHs from the 31 re-plans

compared with the corresponding DVHs from the clinical plans. Re-planned PTV dose was
statistically equivalent to clinical dose and showed a significant improvement in CI (Table 8). Replans also significantly decreased Dmean of both femoral heads by an average of 2.76 (left; p < 0.001)
and 2.50 Gy (right; p < 0.001). A statistically significant increase (p = 0.007) in re-planned right
femoral head Dmax was observed. However, D2 serves as a more stable surrogate for maximum dose
since Dmax represents a point dose that is susceptible to interpolation errors, especially in large dose
gradients. Compared with the clinical plans, the re-planned D2 values were 0.91(p = 0.02) and 0.56
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Gy (p = 0.16) lower for the left and right femoral heads respectively. Lastly, the mean dose to the
penile bulb decreased by an average of 4.0 Gy (p < 0.001) in the re-plans.

Figure 10: Average PTV and secondary OAR DVHs of the 31 re-planned patients comparing the
clinical plans (solid lines) and re-plans (dashed lines). Note the penile bulb was not segmented in 3
of the 31 patients.
The average bladder and rectum DVHs from the re-plans and the clinical plans are shown in
Figure 11. The re-planned bladder and rectum dose was statistically lower (p < 0.001) than the
clinical plan dose for each dose-volume observed (Table 9). This resulted in an average decrease in
mean dose of 7.81 (p < 0.001) and 9.41 Gy (p < 0.001) for the bladder and rectum respectively.
Statistical results from comparing KBP model and re-planned bladder and rectum dose are
shown in Table 10. Overall, seven of the ten predicted bladder and rectum dose-volumes were
statistically equivalent to the attained re-planned values. The re-planned D10 dose-volumes of the
bladder and rectum were on average 1.06 (p = 0.03) and 0.82 Gy (p = 0.04) higher respectively than
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the KBP model predicted values. Additionally, the KBP model predicted D65 of the rectum were on
average 1.74 Gy lower (p = 0.03) than the re-planned values.
Table 8: Statistical results of the dose comparison between the clinical plans and re-plans for the
PTV and secondary OARs. While the PTV and femoral head dose metrics were averaged over the
31 patients, the penile bulb was averaged over the 28 patients in which it was segmented.
Mean
Dose Metric
Wilcoxon p-value
Re-plan – Clinical
PTV
D2 (cGy)
8.8
0.62
D50 (cGy)
-0.4
0.98
D98 (cGy)
21.9
0.37
Dmin (cGy)
-160.1
0.08
Dmean (cGy)
0.6
0.95
Dmax (cGy)
20.7
0.43
V95 (%)
0.06
0.89
V98 (%)
0.07
0.98
V100 (%)
-0.2
0.22
V107 (%)
-0.4
0.80
HI
-0.002
0.84
CI
-0.07
0.03*
Left Femoral Head
D2 (cGy)
-91.2
0.02*
Dmax (cGy)
80.8
0.11
Dmean (cGy)
-275.7
< 0.001*
Right Femoral Head
D2 (cGy)
-55.6
0.16
Dmax (cGy)
127.0
0.007*
Dmean (cGy)
-249.7
< 0.001*
Penile Bulb
Dmean (cGy)
-404.9
< 0.001*
*Indicates a statistically significant result of p < 0.05

3.3

DISCUSSION
This study showed the KBP models utilizing either plan database predicted a significant

improvement in both bladder and rectum dose compared with clinical plans. Concretely, the two
KBP models predicted that more than 7 and 8 Gy dose decreases to the bladder and rectum
respectively were possible. These observed improvements are consistent with previous results from
similar KBP models for prostate cancer.40,68,74 The large dose reductions again reveal the presence of
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Figure 11: Average DVHs over the 31 patients of the bladder and rectum for the clinical plans (solid
lines) and re-plans (dashed lines).
sub-optimal clinical plans, resulting from the inconsistent nature of current inverse planning
processes. This emphasizes the need for planning quality control methods, such as KBP, in clinical
workflows to consistently achieve the best treatment plans for each patient.
When comparing differences between the two individual KBP methods, the MCOD model
predicted significantly lower bladder dose-volumes than the CPD model. Averaged over the five
bladder dose-volumes, the MCOD KBP model predicted dose 3.75 Gy less than the corresponding
CPD KBP model. While the MCOD KBP model did not predict statistically lower dose-volumes for
every rectum dose-volume observed, it predicted an average of 1.04 Gy lower rectum dose than the
CPD KBP model for D50 and D65. Also, the results from the re-planning study affirm the
achievability of these lower MCOD KBP dose-volume predictions. Therefore, this study shows how
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a KBP model using a database of Pareto plans can lead to a higher degree of plan quality than a
clinical plan database overall.
This study supplements and advances the implications from Wang et al.’s validation of the
OVH KBP model using an in-house MCO protocol with consistent prostate planning priorities.69
They realized the shortfalls of evaluating the accuracy of planning quality assurance methods by
comparing predictions with the potentially sub-optimal clinical plans. However, their set of Pareto
plans was generated based on a hierarchical wish-list that prioritized certain OAR sparing over
others, which they suspect may have led to an underestimation of bladder dose. Our study used a
uniformly weighted MCO planning protocol within a commercial TPS to generate consistent Pareto
plans. This study also quantified the degree to which an OVH KBP method can be improved by
using a Pareto plan database compared to using a clinical, inversely optimized plan database.
Further, these more optimal dose-volume predictions obtained through the MCOD KBP model
were shown to be achievable through traditional inverse optimization.
Table 9: Average differences in re-planned and clinical dose values over the 31 patients with
Wilcoxon test results for the primary OARs.
Wilcoxon p-value
Mean
Re-plan
Dose Metric
Re-plan – Clinical
vs.
(cGy)
Clinical
Bladder
D10
-584
< 0.001*
D30
-1184
< 0.001*
D50
-939
< 0.001*
D65
-833
< 0.001*
D80
-703
< 0.001*
Dmean
-781
< 0.001*
Rectum
D10
-345
< 0.001*
D30
-1223
< 0.001*
D50
-1543
< 0.001*
D65
-1366
< 0.001*
D80
-857
< 0.001*
Dmean
-941
< 0.001*
*Indicates a statistically significant result of p < 0.05

43

This suggests that institutions without MCO capabilities could leverage external Pareto plan data in
an existing KBP model to achieve treatment plans more optimal than those predicted by historical
clinical plans. In other words, a MCO-driven KBP model can be made portable and used to achieve
MCO-type plans through traditional inverse optimization.
Table 10: Dosimetric and statistical results for evaluating prediction performance and achievability.
Wilcoxon p-value
Number
Mean
Re-plan
Dose Metric
Of
Re-plan – Prediction
vs.
Predictions
(cGy)
Prediction
Bladder
D10
31
106
0.03*
D30
27
-5
0.77
D50
18
-12
0.65
D65
13
-165
0.13
D80
9
17
0.95
Rectum
D10
31
82
0.04*
D30
31
-174
0.23
D50
30
-13
0.52
D65
23
-174
0.03*
D80
13
-151
0.12
*Indicates a statistically significant result of p < 0.05

Our study shows that predictions from an OVH KBP model can be improved through the
use of a consistently generated Pareto plan database without compromising prediction achievability
or accuracy. However, we did not find the MCOD model to be more optimal in each analyzed dosevolume, namely the two high-dose rectum volumes. It is possible the CPD model predicted lower
doses for rectum D10 and D30 due to varying clinical priorities placed on the rectum. Conversely, it
may be a result of the fixed planning priorities imposed on the Pareto plans of the MCOD. The
minimum dose constraint to the target used in the MCO planning protocol (Table 2) likely serves to
increase the dose to rectum volumes close to the target. This could suggest a refinement of the
Pareto plan generation, such as additional trade-off objectives emphasizing high-dose rectal
volumes, could further improve these rectum dose-volume predictions.
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Planning efficiency was not accounted for or analyzed in the present study as the main
purpose was to investigate the effects of utilizing a dose database of improved quality and
consistency on KBP performance. The present workflow was also not optimized for efficiency.
However, given the previous findings of KBP methods improving planning efficiency, it would
seem reasonable that incorporating another dose database into an existing KBP protocol would not
compromise the method from an efficiency standpoint. However, an examination on treatment
planning efficiency of a KBP method with a separately constructed plan database is needed to verify
this claim.
In order to further improve KBP model performance, a logical progression of the OVHdriven KBP dose-volume prediction method would be the development of an OVH-based KBP
prediction tool for equivalent uniform dose (EUD) planning objectives. The accurate prediction of
an optimally achievable EUD objective could further improve patient-specific KBP plan quality.
Additionally, as with all KBP planning methods, the plan databases may be continuously updated to
include high-quality plans generated via the KBP method.
3.4

CONCLUSIONS
The results from this study showed the dosimetric advantages of an OVH-driven KBP

model using either a clinical plan database or a Pareto plan database. This study also demonstrated
that a Pareto plan database can produce lower dose-volume KBP predictions than a clinical plan
database without jeopardizing achievability. Five out of five bladder and two out of five rectum
dose-volume predictions were found to be more optimal using the MCOD compared with the
conventional CPD. Overall, dose-volume predictions were shown to be achievable regardless of
plan database origin, with average differences of no more than 1.74 Gy with the re-planned bladder
and rectum dose-volumes. Further, these results indicate the possibility of achieving MCO-type
plans through inverse planning optimization.
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CHAPTER 4. CONCLUSIONS
4.1

SUMMARY OF FINDINGS
The main goal of this study was to evaluate the extent to which the performance of an

OVH-driven KBP model for predicting dose-volumes is affected by plan quality deficiencies and
variations in the plan database. Sub-optimal and inconsistent treatment plans in a large database of
prostate patients due to inter-planner subjectivity were controlled for by applying a uniform MCO
planning protocol to create a balanced Pareto optimal plan for each database patient. KBP model
dose-volume predictions generated from the clinical, manually-optimized plan data (i.e. the CPD)
were compared to those derived from the database of Pareto plans (i.e. the MCOD). Achievability
of those dose-volume predictions were verified by re-planning a subset of randomly selected patients
with the KBP model predictions as planning goals.
When establishing the distance-to-dose relationship for querying new patients against the
database for patients with similar anatomies (see Chapter 2), we observed a sizable variation in dose
a specific fractional OAR volume received (i.e. a DVH point) at a given distance away from the PTV
surface (i.e. a OVH point). These large spreads in the DVH-OVH correlations for a fractional OAR
volume could lead to less accurate and namely less achievable dose-volumes in an OVH-driven KBP
model. Therefore, we investigated the influence of second-order factors on this distance-to-dose
correlation variation while again accounting for sub-optimal planning due to inter-planner bias. We
found the in-field OAR volume correlated strongest with MCOD dose for each observed dosevolume of both the bladder and rectum. Other second-order variables, such as prescription dose and
bladder and rectum fill volumes, did not correlate with OAR dose. The derivative of the OVH and
PTV volume moderately correlated with OAR dose. Recalculating the OVH to only consider OAR
volume within the treatment fields resulted in an overall strengthening in the distance-to-dose
correlation of the bladder and rectum. This in-field OVH removed data points that would likely
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result in unachievably low dose-volume predictions and was selected to be the feature querying
metric for the KBP model used in this study.
Chapter 3 detailed the results from comparing an OVH-based KBP model using a clinical
plan database (CPD) with one using a Pareto plan database (MCOD). The MCOD KBP model
predicted statistically lower dose than the CPD KBP model for all five bladder dose-volumes and
two of five rectum dose-volumes observed. A re-planning study confirmed the achievability of these
KBP predictions while maintaining statistically similar PTV and secondary OAR dose as the original
clinical plans. Therefore, a database of uniform Pareto plans can produce more optimal dose-volume
predictions that lead to improved plan quality compared with a conventional clinical plan database.
The hypothesis of this study was that OVH-driven KBP bladder and rectum dose-volume
predictions derived from the MCOD database of Pareto plans versus those derived from the CPD
database of inversely optimized clinical plans would result in plans with statistically improved (p <
0.017) sparing of the bladder and rectum, while also maintaining statistically equivalent PTV and
secondary OAR dose. To this end, the results fully support this hypothesis for the bladder as the
MCOD model produced achievable and statistically lower predictions than the CPD model for each
dose-volume considered. As for rectum, however, MCOD model predictions were statistically lower
than those from the CPD model for only D50 and D65 dose-volumes. Nonetheless, the MCOD KBP
model led to improved and achievable overall bladder and rectum dose sparing, while still
maintaining statistically similar PTV and secondary OAR dose.
4.2

LIMITATIONS
One limitation of this work is the size of the patient database. Naturally, the larger the

patient database, the more robust a KBP method should be. Boutilier et al.’s study found that more
than 200 samples gives the most consistent OVH-driven KBP model dose-volume predictions.74
However, they also show a database size of 100 patients still results in a similarly consistent and
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accurate KBP model compared with a 200 patient database. Specifically, a KBP model with a sample
size of 100 patients produced a similar number of “over-predictions” (i.e. predictions where a
dosimetric value was worse than the clinical value) for bladder and rectum dose-volumes compared
to a model with 200 patients. Given time constraints, the working sample size of 124 was
predetermined to yield adequate model performance and statistical power for the purposes of this
project.
This study also restricts database patients to those with only one prescribed PTV. This
aspect has been discussed by previous groups dealing distance-to-dose KBP methods similar to the
one used in this study.44,69 For cases that require more than one segmented PTV, such as
simultaneous integrated boosts (SIB), an OAR will have separate OVHs for each defined PTV with
likely differing prescription doses. However, the model in this study could theoretically be adapted
to predict dose-volumes for SIB treatments by compiling a database of previous SIB patients. Wang
et al. provides an example of such a formalism.69 This logic extends to other, more complex
treatment sites as well (e.g. head and neck), although model testing would still be needed to confirm
the method’s clinical viability.
There was also not a comprehensive analysis of how the in-field OVH KBP predictions
compared to the nominal OVH KBP predictions in this study. Despite being out of the scope of
this thesis, results from qualitative inspection comparing the two OVH methods in the re-planning
study can be found in the supplemental material (see Appendix F). A preliminary statistical analysis
between the achieved re-planned and the predicted nominal OVH dose-volumes can also be found
in Appendix G. Additionally, Petit et al. performed a similar comparison study with IMRT pancreatic
adenocarcinoma patients and they found the in-field OVH produced more accurate and achievable
liver dose-volume predictions than the standard OVH. These findings suggest a similar discovery is
likely with the VMAT prostate patients in this study.
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Since in-field OVH-driven KBP dose-volume predictions were not made for patients with
less than the given in-field OAR volume threshold, there were missing statistical data when
evaluating the prediction achievability in the re-planning study. The signed-rank Wilcoxon statistical
function used for these comparisons cautions the inability to perform a normal approximation with
a sample size of less than 10. This warning only arises for D80 of the bladder, which had only 9 KBP
predictions. Although these missing data do decrease the statistical power of the Wilcoxon test, 31
re-planned patients is a sufficient overall sample size to confidently interpret the results. Further, a
pilot study determined that 30 or more patients was an adequate sample size in order to detect a
significant difference of about 2 Gy with 80% power.
Another limitation of this study is the lack of biological plan quality metrics (e.g. target
control probability, normal tissue complication probability, secondary cancer complication
probability etc.) that could be used to evaluate potential outcome differences in two treatment plans.
The purpose of this study was to assess dosimetric differences between plans only. Although outside
the scope of this project, investigation into the differences in biology-based metrics between both
sets of KBP predictions and results from the re-planning study could supplement the dosimetric
findings in this study.
4.3

FUTURE WORK
The next logical and immediate step for this project would be to further identify outliers

present in the patient database. This was addressed primarily through the in-field OVH in the
present study. However, one could imagine taking other factors that were found to moderately
influence the distance-to-dose relationship (e.g. dOVH and PTV volume) and incorporating them
into the dose-volume prediction through multiple linear regression, for example.
Another direction that one could take is the investigation of a more optimal MCO planning
protocol than the one used in this work. While the MCO balance plan yields a plan independent of
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inter-planner variations, there likely exist Pareto plans that are more optimal for a specific OAR. The
MCO planning protocol applied to each database patient in this study produced uniformly
consistent Pareto plans, regardless of relative OAR priorities. This is in contrast to the manually
optimized clinical plans, where physician preference can result in plans where one particular OAR
was emphasized at the expense of the other. The independence of OAR sparing priorities in the
MCO planning protocol may explain, at least partially, why the CPD model predicted statistically
lower D10 and D30 rectum dose-volumes. Regardless, a custom optimization protocol could be
developed to search each patient’s Pareto surface based on certain planning priorities, which could
result in even more optimal KBP dose-predictions, albeit at the expense of increased computational
overhead.
As mentioned in Chapter 1.1.3, KBP methods can be applied at multiple levels of the
treatment planning process. The KBP method developed in this study can be adapted for pre- or
post-planning quality assurance. Therefore, clinically implementing this KBP method for either preplanning dose-volume predictions or flagging sub-optimal plans post-planning is a natural
progression from this work. Further, the extension of this KBP structure to other treatment sites
should be investigated before considering clinical implementation.
As part of the clinical validation of this KBP model, a study would need to be done verifying
the deliverability of the KBP-assisted plans (e.g. the re-plans in this study). While not studied in
detail, a cursory inspection of the re-plans indicated a sizeable increase in the MUs required relative
to the original clinical plans. The amount of required MUs is a general, although not exact, indicator
of plan complexity as defined by the modulation complexity score.75,76 The increased complexity of
the re-plans trying to achieve the KBP model dose-volume predictions may affect the plans ability to
pass quality assurance tests. As the re-plans were not planned under the exact same conditions (from
a technical perspective e.g. different TPS, machine, etc.) as the clinical plans, a quality assurance
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assessment of the re-plans is needed to confirm the clinical viability of the resulting plans. This,
however, was outside the purpose and scope of the current project.
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APPENDIX A. EXTRANEOUS MATERIALS AND METHODS
A.1

PATIENT ANONYMIZATION
The process of patient data anonymization is an important step in performing treatment

planning research. This task was laborious in this study due to the various locations patient data can
reside within Mary Bird Perkins Cancer Center (MBPCC) depending on the treatment status of a
particular patient. In other words, a patient could be in the middle of his or her treatment or fully
completed, meaning the DICOM data could be active or archived respectively. For the purposes of
this project, active patient DICOM data within MBPCC can most easily be obtained from within
Mobius3D (Mobius Medical Systems LP, Houston, TX), a software application for quality assurance
and treatment plan verification that also features a DICOM anonymization tool. On the other hand,
archived patient data housed in MBPCC’s radiation oncology information system MOSAIQ (Elekta,
Stockholm, Sweden) must be restored before anonymization.
At MBPCC, the DICOM data is transferred to Mobius3D for a plan check once a plan has
been completed and physician-approved in Pinnacle. This patient data and the plan report remain in
the plan check list for a given amount of time before the data is archived to MOSAIQ. From this
list, a patient’s anonymized DICOM data can be downloaded using the Mobius3D anonymization
feature. Therefore, this plan check list was first searched for suitable database patients. If a patient
met the previously defined selection criteria, the anonymized DICOM data was downloaded before
being transferred to and imported into RayStation.
After the patient search through the Mobius3D plan check list was exhausted, archived
database candidates were searched using MOSAIQ. A report categorized by primary diagnosis was
run in MOSAIQ in order to selectively search the entire MOSAIQ database for a cohort of possible
candidates. The report was configured to return a list of all patients treated within a specified time
frame in the MBPCC system with a primary cancer diagnosis of “Prostate.” Patients with statuses
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other than “New” were reviewed for database selection (i.e. only patients with clinically-approved
treatment plans). The plan summary of each potential database patient was examined to determine
whether selection criteria were met. The DICOM data of patients meeting the selection criteria
needed to be restored in the TPS.
Patient data can be backed up to electronic media in Pinnacle. Patients at MBPCC are
archived to the MOSAIQ Data Director (MDD), an integrated image and data archiving software
system. When patient data is ready to be archived, all image sets and DICOM-RT files associated
with that patient are backed up to MDD. Specifically, all archived image sets are listed along with a
Pinnacle-specific .tar file that contains header information needed to restore the patient DICOM
data to Pinnacle. In order to restore an archived database patient to Pinnacle, the original primary
image set and the corresponding .tar file need to be downloaded and pushed to the Pinnacle server.
Once the .tar file was transferred to the Pinnacle server, the patient was restored via the
header file contained in the tarball. The primary CT set transferred from MOSAIQ was then
imported into that patient. However, for the DICOM image set to be exported to Mobius3D with
the same instance as the other DICOM-RT files (i.e. so that all DICOM files can be properly
imported into RayStation), the restored DICOM image set must be assigned as the primary image
set of the patient. This was done by copying the restored plan to the imported DICOM image set,
which produced an identical plan to the restored plan except with no dose. The dose was
recomputed for both VMAT beams and the patient data was ready to be exported to Mobius3D for
anonymization.
All patient data was anonymized in Mobius3D and imported into RayStation in this fashion
until the target number of database patients was achieved. In total, 124 database patients were
imported into RayStation for this study.
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A.2

DATABASE STANDARDIZATION AND PREPARATION
There are numerous benefits to standardizing nomenclature for body and organ structures,

DVH metrics, toxicity, units etc. in radiation therapy. For example, standardizing RT nomenclature
can enable easy pooling of data across institutions as well as minimize systematic communication
errors within a single institution. With the growing prevalence of large data studies and clinical trials,
the American Association of Physicists in Medicine recently approved the formation of Task Group
No. 263 for Standardizing Nomenclature for Radiation Therapy. For this study, the nomenclature
standardization of select patient data objects was necessary for scripting automation and analysis
purposes.
Each anonymized patient imported into RayStation underwent a series of modifications in
order to standardize each patient for future use, including OVH computations and DVH data
extraction. First, the Tissue Name under the regions of interest (ROI) properties for each specified
ROI was designated according to the list in Table 11, which were largely adapted from the RTOG
0126 protocol.77 These labels would serve as object identifiers in future automation routines, as the
names of the structures created by original planners were not uniform. Additionally, each External
ROI was modified in RayStation to encompass the entire patient surface included in the CT set.
Each patient image set was required to have an assigned Imaging System. Therefore, each
database patient’s Imaging System was set to the Generic CT table used to commission the TPS.
Then, each imported plan was copied and renamed “MCO_pw,” which would serve as the plan file
where the MCOD plan would be generated for each database patient. Plan properties were set to
uniquely differentiate the MCO plan from the clinical plan and each MCOD plan was set to the
same treatment machine. From there, MCO plan development commenced.
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Table 11: List of structures used in this study and their assigned standardized Tissue Name labels.
The in-field structures were created for computing the in-field OVH in this study as will be
discussed in A.3.
Patient Structure
Standardized Tissue Name
PTV
PTV
Bladder
BLADDER
Rectum
RECTUM
Left Femoral Head
FEMUR_LT
Right Femoral Head
FEMUR_RT
Penile Bulb
PENILE_BULB
External
EXTERNAL
In-field Bladder
BLADDER_IN
In-field Rectum
RECTUM_IN
A.3

NOMINAL AND IN-FIELD OVH COMPUTATIONS
An IronPython script was written to automate the OVH computation process from within

RayStation. The script was designed to loop through a list of patients in the RayStation database and
compute the OVHs for the bladder and rectum of each patient. The script takes a list of unique
patient IDs as input and outputs the bladder and rectum OVH data in a patient-specific text files.
The script algorithm takes advantage of the built-in ROI tools of RayStation by first
selecting and copying the PTV ROI in the plan, which serves as the working copy of the original
PTV contour. Then, ROI algebra is performed to find the intersections between the bladder and
PTV ROIs and between the rectum and PTV ROIs, which represent the bladder and rectum volume
overlapping with the PTV respectively. Then those overlap volumes are divided by the total volumes
of the bladder and rectum ROIs respectively, yielding the bladder and rectum OVH values at a 0 cm
expansion distance. Three data items are then written to a patient-specific text file: the current OVH
expansion/contraction distance (cm), the bladder OVH value, and the rectum OVH value. The
newly created ROIs required for this process are deleted before moving to the next OVH data point
to prevent memory leaks. Then a new copy of the PTV is created with a surface uniformly expanded
by 1 mm and the process continues as just described. This entire process continues until both the
bladder and rectum OVH values are above 85% volume.
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Once the OVH expansions are completed for both bladder and rectum ROIs, the same
iterations described previously are executed, except the PTV ROI surface is uniformly contracted in
1 mm steps. This process continues until both the bladder and rectum OVH values are 0%. At this
point, the text file contains both bladder and rectum OVHs from 0% to at least 85% volumes. This
script prevented the computation from continuing until 100% volume overlap due to time efficiency
and the specific needs of this project (i.e. largest value needed was 80% to predict the D80 dosevolume). The PTV ROI copying process becomes prohibitively time-consuming the larger the
expansion value presumably due to the memory requirements from the large number of structure
voxels.
This script would then loop to the next database patient in the input list and begin the OVH
computation for that patient. The script would continue in this manner until each patient in the list
was complete.
In order to compute the in-field OVHs for the bladder and rectum ROIs, in-field ROIs for
each structure needed to be generated. A separate IronPython script was written to consistently
automate this process like the OVH computation script. In-field volume was defined as ROI volume
within the transverse planes located 6 mm (to approximate beam penumbra at depth) superior and
inferior to the most superior and inferior aspects of the PTV, respectively. Therefore, to create these
in-field ROIs, a copy of the PTV ROI was expanded by 6 mm in the superior and inferior directions
and 15 cm in the left, right, anterior, and superior directions. Then the intersections between the
bladder and new PTV ROI and between the rectum and new PTV ROI were created to represent
the in-field bladder and rectum ROIs. An example of the ROIs generated from this script is shown
in Figure 12. This process was repeated for each database patient.
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BLADDER

RECTUM

Estimation
of
Treatment
Fields

PTV

RECTUM_IN

BLADDER_IN

PENILE_BULB
RECTUM

Figure 12: Sagittal CT slice of a database patient showing the estimation of the treatment fields. The
horizontal lines are part of the ROI created from the original PTV contour to represent the
treatment fields. Given Tissue Names are listed with their corresponding ROIs, with the in-field
OAR portions indicated by “_IN.” Note the femoral heads are not visible and are located to the left
and right of the shown CT slice.
The OVH computation script was modified and adapted to compute the in-field OVHs for
the bladder and rectum ROIs in each patient. The major adjustment was to select the
“BLADDER_IN” and “RECTUM_IN” planning objects instead of the nominal objects at the
beginning of the script. The in-field OVH computation process was identical to the standard OVH
script, except the in-field OVH script continued expanding until 100% of the in-field bladder and
rectum ROIs were overlapped by the expanded PTV. Again, patient-specific text files were written
to contain the in-field OVH data for both the in-field bladder and rectum ROIs.
A.4

STATISTICAL ANALYSIS OF CLINICAL AND PREDICTED DOSE-VOLUMES
The Wilcoxon signed-rank test used in this study is a non-parametric test for testing the null

hypothesis that two related paired samples come from the same distribution. It is the non-parametric
version of the student t-test. Deciding to use this particular test was based on results from testing
data distribution assumptions. The use of parametric statistical tests assumes the data are normally
distributed and the variances of the compared samples are similar. Therefore, prior to the individual
statistical comparisons performed on the dose-volume distributions of the clinical, CPD, and
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MCOD data (detailed in Chapter 3.1), normality and omnibus statistical tests were performed on the
three distributions of data. This statistical analysis process was adapted and based on the methods
described by Chaikh et al.78 Also, all statistical tests were performed using the statistical functions
module in SciPy (scipy.stats), an open-source Python library for scientific computing.
Out of the numerous possible statistical tests designed to assess normality, the Shapiro-Wilk
test was used in this work (scipy.stats.shapiro). The Shapiro-Wilk test tests the null hypothesis that
the data was drawn from a normal distribution, where a p-value of less than 0.05 indicates a
significant difference between the test data and a normal distribution (i.e. the data is likely nonnormal). Normality tests are often complemented by measuring the skewness and the kurtosis of the
data distributions. The skewness describes the symmetry of the data while kurtosis quantifies the
spread or peak sharpness of the distribution. A statistical test based on D’Agostino and Pearson’s
test was used in this study to further evaluate normality of the distributions of data
(scipy.stats.normaltest). This test combines skew and kurtosis tests to produce an omnibus test of
normality where again, a p-value of less than 0.05 indicates a significant difference (i.e. the data is
likely non-normal).
These normality statistical tests were performed on each of the three distributions of data:
the original, clinical data, the CPD-derived KBP predictions, and the MCOD-derived KBP
predictions. These tests yielded p-values for each of the five bladder and five rectum dose-volumes
observed in this study and can be seen in Table 12. These results indicated that a large majority of
the data sets tested were likely non-normal distributions. To further support this interpretation, each
data set was visually inspected via histograms and compared with fitted normal distributions. Two
representative examples can be seen in Figure 13. Boxplots of the data may also be used as a visual
tool when determining normality. The data visualization confirmed the normality tests and the
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decision was made to proceed with non-parametric statistical tests. Uniform variance was not tested
in this study since a repeated measures design was used.
Table 12: Normality statistical test p-values for the three distributions of data. A statistically
significant result may be interpreted as the given data likely representing a non-normal distribution.
Clinical Data
CPD Model
MCOD Model
Dose-Volume N†
Shapiro
Normal
Shapiro
Normal
Shapiro
Normal
Bladder
D10
123 < 0.001* < 0.001* < 0.001* < 0.001* < 0.001* < 0.001*
D30
107
0.01*
0.046*
0.001*
0.002 < 0.001* < 0.001*
D50
75
0.03*
0.10
< 0.001*
<0.001* < 0.001*
0.006*
D65
51
0.03*
0.03*
< 0.001*
<0.001* < 0.001* < 0.001*
D80
34
0.08
0.03*
< 0.001*
<0.001* < 0.001* < 0.001*
Rectum
D10
123 < 0.001* < 0.001* < 0.001*
0.43
< 0.001* < 0.001*
D30
123
0.25
0.72
< 0.001* < 0.001* < 0.001* < 0.001*
D50
116
0.86
0.77
< 0.001*
0.005* < 0.001* < 0.001*
D65
89
0.63
0.76
< 0.001* < 0.001* < 0.001* < 0.001*
D80
48
0.31
0.28
< 0.001*
0.005* < 0.001* < 0.001*
*Indicates a statistically significant result of p < 0.05
† N represents the number of database patients where an in-field OVH-driven KBP prediction was possible
i.e. predictions were not made for patients with fractional in-field OAR volumes less than the given dosevolume

After carrying out the normality statistical test, an omnibus test was performed. Conducting
an omnibus test is typically the first step when performing more than one statistical comparison. A
total of three comparisons were made in this part of the study: Clinical vs. CPD, Clinical vs. MCOD,
and CPD vs. MCOD distributions. The omnibus test checks whether there exists a difference
between any of the datasets. In other words, it tests whether all datasets are statistically equivalent. If
no statistically significant result is achieved, there is no need to continue to one-on-one comparisons
between the individual datasets.
This study used the Friedman test to conduct the omnibus test
(scipy.stats.friedmanchisquare), which tests the null hypothesis that repeated samples of the same
individuals have the same distribution. Therefore, a statistically significant result means it is likely a
difference exists between the distributions tested. This test is the non-parametric equivalent of the
repeated measures analysis of variance (ANOVA) test. The p-values resulting from the Friedman test
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(a)

(b)

Figure 13: Representative examples of data visualization via density distribution histograms along
with estimated normal curves, plotted using the mean and standard deviation of the data. (a) is an
example of a distribution determined to likely be non-normal and (b) is an example of a distribution
deemed to be normal.
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are shown in Table 13. Each bladder and rectum dose-volume yielded a statistically significant result,
indicating the need to perform one-on-one comparisons. This was accomplished via multiple
Wilcoxon signed-rank tests, the results of which are detailed in Chapter 3.1.3.
Table 13: Results from the omnibus test. Each dose-volume yielded statistically significant results,
indicating a difference likely exists between the three distributions of data.
Friedman Test
Dose-Volume N†
p-value
Bladder
D10
123
<0.001*
D30
107
<0.001*
D50
75
<0.001*
D65
51
<0.001*
D80
34
<0.001*
Rectum
D10
123
<0.001*
D30
123
<0.001*
D50
116
<0.001*
D65
89
<0.001*
D80
48
<0.001*
*Indicates a statistically significant result of p < 0.05
† N represents the number of database patients where an in-field OVH-driven KBP prediction was possible
i.e. predictions were not made for patients with fractional in-field OAR volumes less than the given dosevolume
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APPENDIX B. CPD VERSUS MCOD NOMINAL DVH-OVH
CORRELATIONS

Figure 14: Nominal DVH-OVH correlation (R) using the CPD DVH data (circles) and the MCOD
DVH data (squares) for the 30% dose-volume of the bladder.

Figure 15: Nominal DVH-OVH correlation (R) using the CPD DVH data (circles) and the MCOD
DVH data (squares) for the 50% dose-volume of the bladder.
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Figure 16: Nominal DVH-OVH correlation (R) using the CPD DVH data (circles) and the MCOD
DVH data (squares) for the 65% dose-volume of the bladder.

Figure 17: Nominal DVH-OVH correlation (R) using the CPD DVH data (circles) and the MCOD
DVH data (squares) for the 80% dose-volume of the bladder.
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Figure 18: Nominal DVH-OVH correlation (R) using the CPD DVH data (circles) and the MCOD
DVH data (squares) for the 30% dose-volume of the rectum.

Figure 19: Nominal DVH-OVH correlation (R) using the CPD DVH data (circles) and the MCOD
DVH data (squares) for the 50% dose-volume of the rectum.
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Figure 20: Nominal DVH-OVH correlation (R) using the CPD DVH data (circles) and the MCOD
DVH data (squares) for the 65% dose-volume of the rectum.

Figure 21: Nominal DVH-OVH correlation (R) using the CPD DVH data (circles) and the MCOD
DVH data (squares) for the 80% dose-volume of the rectum.
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Table 14: Summary of the Pearson correlation coefficients for the distance-to-dose relationships
formed with the CPD and MCOD dose data. The nominal OVH data was used for these
correlations. The MCOD dose produced a stronger correlation with distance overall, most
noticeably in the rectum. This is most likely due to the removal of the inter-planner subjectivity
present in the CPD dose data.
DVH-OVH R
Dose-Volume
CPD MCOD
Bladder
D30
-0.91 -0.92
D50
-0.84 -0.83
D65
-0.73 -0.74
-0.65 -0.66
D80
Mean
-0.78 -0.79
Rectum
D30
-0.75 -0.94
D50
-0.67 -0.86
D65
-0.68 -0.78
D80
-0.65 -0.70
Mean
-0.69 -0.82
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APPENDIX C. COLOR BAR CORRELATION PLOTS OF SECONDORDER FACTORS

Figure 22: Color bar scatter plot for distance-to-dose relationship for 30% of the bladder, where the
color-mapped variable is the derivative of the OVH.

Figure 23: Color bar scatter plot for distance-to-dose relationship for 50% of the bladder, where the
color-mapped variable is the derivative of the OVH.
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Figure 24: Color bar scatter plot for distance-to-dose relationship for 65% of the bladder, where the
color-mapped variable is the derivative of the OVH.

Figure 25: Color bar scatter plot for distance-to-dose relationship for 80% of the bladder, where the
color-mapped variable is the derivative of the OVH.
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Figure 26: Color bar scatter plot for distance-to-dose relationship for 30% of the rectum, where the
color-mapped variable is the derivative of the OVH.

Figure 27: Color bar scatter plot for distance-to-dose relationship for 50% of the rectum, where the
color-mapped variable is the derivative of the OVH.
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Figure 28: Color bar scatter plot for distance-to-dose relationship for 65% of the rectum, where the
color-mapped variable is the derivative of the OVH.

Figure 29: Color bar scatter plot for distance-to-dose relationship for 80% of the rectum, where the
color-mapped variable is the derivative of the OVH.
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Figure 30: Color bar scatter plot for distance-to-dose relationship for 30% of the bladder, where the
color-mapped variable is the prescription dose.

Figure 31: Color bar scatter plot for distance-to-dose relationship for 50% of the bladder, where the
color-mapped variable is the prescription dose.
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Figure 32: Color bar scatter plot for distance-to-dose relationship for 65% of the bladder, where the
color-mapped variable is the prescription dose.

Figure 33: Color bar scatter plot for distance-to-dose relationship for 80% of the bladder, where the
color-mapped variable is the prescription dose.
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Figure 34: Color bar scatter plot for distance-to-dose relationship for 30% of the rectum, where the
color-mapped variable is the prescription dose.

Figure 35: Color bar scatter plot for distance-to-dose relationship for 50% of the rectum, where the
color-mapped variable is the prescription dose.
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Figure 36: Color bar scatter plot for distance-to-dose relationship for 65% of the rectum, where the
color-mapped variable is the prescription dose.

Figure 37: Color bar scatter plot for distance-to-dose relationship for 80% of the rectum, where the
color-mapped variable is the prescription dose.
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Figure 38: Color bar scatter plot for distance-to-dose relationship for 30% of the bladder, where the
color-mapped variable is the PTV volume.

Figure 39: Color bar scatter plot for distance-to-dose relationship for 50% of the bladder, where the
color-mapped variable is the PTV volume.
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Figure 40: Color bar scatter plot for distance-to-dose relationship for 80% of the bladder, where the
color-mapped variable is the PTV volume.

Figure 41: Color bar scatter plot for distance-to-dose relationship for 30% of the rectum, where the
color-mapped variable is the PTV volume.

82

Figure 42: Color bar scatter plot for distance-to-dose relationship for 50% of the rectum, where the
color-mapped variable is the PTV volume.

Figure 43: Color bar scatter plot for distance-to-dose relationship for 80% of the rectum, where the
color-mapped variable is the PTV volume.
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Figure 44: Color bar scatter plot for distance-to-dose relationship for 30% of the bladder, where the
color-mapped variable is the bladder volume.

Figure 45: Color bar scatter plot for distance-to-dose relationship for 50% of the bladder, where the
color-mapped variable is the bladder volume.
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Figure 46: Color bar scatter plot for distance-to-dose relationship for 65% of the bladder, where the
color-mapped variable is the bladder volume.

Figure 47: Color bar scatter plot for distance-to-dose relationship for 80% of the bladder, where the
color-mapped variable is the bladder volume.
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Figure 48: Color bar scatter plot for distance-to-dose relationship for 30% of the rectum, where the
color-mapped variable is the bladder volume.

Figure 49: Color bar scatter plot for distance-to-dose relationship for 50% of the rectum, where the
color-mapped variable is the bladder volume.
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Figure 50: Color bar scatter plot for distance-to-dose relationship for 65% of the rectum, where the
color-mapped variable is the bladder volume.

Figure 51: Color bar scatter plot for distance-to-dose relationship for 80% of the rectum, where the
color-mapped variable is the bladder volume.

87

Figure 52: Color bar scatter plot for distance-to-dose relationship for 30% of the bladder, where the
color-mapped variable is the rectum volume.

Figure 53: Color bar scatter plot for distance-to-dose relationship for 50% of the bladder, where the
color-mapped variable is the rectum volume.

88

Figure 54: Color bar scatter plot for distance-to-dose relationship for 65% of the bladder, where the
color-mapped variable is the rectum volume.

Figure 55: Color bar scatter plot for distance-to-dose relationship for 80% of the bladder, where the
color-mapped variable is the rectum volume.
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Figure 56: Color bar scatter plot for distance-to-dose relationship for 30% of the rectum, where the
color-mapped variable is the rectum volume.

Figure 57: Color bar scatter plot for distance-to-dose relationship for 50% of the rectum, where the
color-mapped variable is the rectum volume.
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Figure 58: Color bar scatter plot for distance-to-dose relationship for 65% of the rectum, where the
color-mapped variable is the rectum volume.

Figure 59: Color bar scatter plot for distance-to-dose relationship for 80% of the rectum, where the
color-mapped variable is the rectum volume.
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Figure 60: Color bar scatter plot for distance-to-dose relationship for 30% of the bladder, where the
color-mapped variable is the in-field OAR volume.

Figure 61: Color bar scatter plot for distance-to-dose relationship for 50% of the bladder, where the
color-mapped variable is the in-field OAR volume.
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Figure 62: Color bar scatter plot for distance-to-dose relationship for 80% of the bladder, where the
color-mapped variable is the in-field OAR volume.

Figure 63: Color bar scatter plot for distance-to-dose relationship for 30% of the rectum, where the
color-mapped variable is the in-field OAR volume.
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Figure 64: Color bar scatter plot for distance-to-dose relationship for 50% of the rectum, where the
color-mapped variable is the in-field OAR volume.

Figure 65: Color bar scatter plot for distance-to-dose relationship for 80% of the rectum, where the
color-mapped variable is the in-field OAR volume.
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APPENDIX D. NOMINAL VERSUS IN-FIELD OVH DISTANCE-TODOSE CORRELATIONS

Figure 66: DVH-OVH correlation (R) using nominal OVH data (squares) and in-field OVH data
(diamonds) for the 30% dose-volume of the bladder.

Figure 67: DVH-OVH correlation (R) using nominal OVH data (squares) and in-field OVH data
(diamonds) for the 50% dose-volume of the bladder.
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Figure 68: DVH-OVH correlation (R) using nominal OVH data (squares) and in-field OVH data
(diamonds) for the 30% dose-volume of the rectum.

Figure 69: DVH-OVH correlation (R) using nominal OVH data (squares) and in-field OVH data
(diamonds) for the 50% dose-volume of the rectum.
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APPENDIX E. PLAN DATABASE DOSIMETRIC COMPARISON
Table 15: Statistical results of the dose comparison between the two plan databases for the PTV and
secondary OARs. The mean differences between the MCOD and CPD dose metrics were averaged
over the 124 database patients.
Mean
Dose Metric
Wilcoxon p-value
MCOD – CPD
PTV
D2 (cGy)
-140.8
< 0.001*
D50 (cGy)
-124.6
< 0.001*
D98 (cGy)
133.4
< 0.001*
Dmin (cGy)
650.5
< 0.001*
Dmean (cGy)
-101.5
< 0.001*
Dmax (cGy)
-62.3
< 0.001*
V95 (%)
0.56
< 0.001*
V98 (%)
1.40
< 0.001*
V100 (%)
-6.05
< 0.001*
V107 (%)
-0.23
< 0.001*
HI
-0.03
< 0.001*
CI
-0.13
< 0.001*
Left Femoral Head
D2 (cGy)
-2506
< 0.001*
Dmax (cGy)
-2077
< 0.001*
Dmean (cGy)
-2189
< 0.001*
Right Femoral Head
D2 (cGy)
-2492
< 0.001*
Dmax (cGy)
-2058
< 0.001*
Dmean (cGy)
-2187
< 0.001*
Penile Bulb
Dmean (cGy)
-994
< 0.001*
*Indicates a statistically significant result of p < 0.05
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Table 16: Statistical results of the dose comparison between the two plan databases for the primary
OARs. The mean differences between the MCOD and CPD dose metrics were averaged over the
124 database patients.
Wilcoxon p-value
Mean
Re-plan
Dose Metric MCOD – CPD
vs.
(cGy)
Clinical
Bladder
D10
-542
< 0.001*
D30
-879
< 0.001*
D50
-643
< 0.001*
D65
-520
< 0.001*
D80
-473
< 0.001*
Dmean
-581
< 0.001*
Rectum
D10
-137
< 0.001*
D30
-434
< 0.001*
D50
-541
< 0.001*
D65
-578
< 0.001*
D80
-557
< 0.001*
Dmean
-435
< 0.001*
*Indicates a statistically significant result of p < 0.05
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APPENDIX F. PATIENT-BY-PATIENT PREDICTION ACHIEVABILITY
PLOTS

Figure 70: Patient-by-patient data from re-planning study comparing the original, clinical value
(triangle), in-field OVH KBP prediction (square), standard OVH KBP prediction (diamond), and replanned value (circle) for bladder D10.

Figure 71: Patient-by-patient data from re-planning study comparing the original, clinical value
(triangle), in-field OVH KBP prediction (square), standard OVH KBP prediction (diamond), and replanned value (circle) for bladder D30.
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Figure 72: Patient-by-patient data from re-planning study comparing the original, clinical value
(triangle), in-field OVH KBP prediction (square), standard OVH KBP prediction (diamond), and replanned value (circle) for bladder D50.

Figure 73: Patient-by-patient data from re-planning study comparing the original, clinical value
(triangle), in-field OVH KBP prediction (square), standard OVH KBP prediction (diamond), and replanned value (circle) for bladder D65.
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Figure 74: Patient-by-patient data from re-planning study comparing the original, clinical value
(triangle), in-field OVH KBP prediction (square), standard OVH KBP prediction (diamond), and replanned value (circle) for bladder D80.

Figure 75: Patient-by-patient data from re-planning study comparing the original, clinical value
(triangle), in-field OVH KBP prediction (square), standard OVH KBP prediction (diamond), and replanned value (circle) for rectum D10.
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Figure 76: Patient-by-patient data from re-planning study comparing the original, clinical value
(triangle), in-field OVH KBP prediction (square), standard OVH KBP prediction (diamond), and replanned value (circle) for rectum D30.

Figure 77: Patient-by-patient data from re-planning study comparing the original, clinical value
(triangle), in-field OVH KBP prediction (square), standard OVH KBP prediction (diamond), and replanned value (circle) for rectum D50.
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Figure 78: Patient-by-patient data from re-planning study comparing the original, clinical value
(triangle), in-field OVH KBP prediction (square), standard OVH KBP prediction (diamond), and replanned value (circle) for rectum D65.

Figure 79: Patient-by-patient data from re-planning study comparing the original, clinical value
(triangle), in-field OVH KBP prediction (square), standard OVH KBP prediction (diamond), and replanned value (circle) for rectum D80.
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APPENDIX G. PRELIMINARY ACHIEVABILITY RESULTS FOR
NOMINAL VERSUS IN-FIELD OVH PREDICTIONS
Table 17: Statistical results comparing predictions from KBP model using the in-field OVH versus
the nominal OVH feature metric.
Wilcoxon p-value
Mean
In-field
In-field – Nominal
Dose Metric Predictions
vs.
OVH Prediction
Nominal OVH
(cGy)
Bladder
D10
31
-6.9
0.32
D30
27
239.0
0.05*
D50
18
97.6
0.25
D65
13
776.1
0.003*
D80
9
865.2
0.007*
Rectum
D10
31
0.6
0.16
D30
31
33.1
0.14
D50
30
315.4
< 0.001*
D65
23
917.3
< 0.001*
D80
13
1056.2
0.002*
*Indicates a statistically significant result of p < 0.05
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